



PCT/GB 2004 / 0 0 1 8 3 1



INVESTOR IN PEOPLE

BEST AVAILABLE COPY

The Patent Office
Concept House
Cardiff Road

Newport

South Wales

NP10 8QQ

REC'D 22 JUN 2004

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 25 May 2004

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The
Patent
Office

02HAY03 EBO 336-2 D00019
P01/7700 0 00-03100567

Request for grant of a patent

See the notes on the back of this form. You can also
get an explanatory leaflet from the Patent Office to
help you fill in this form)



The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference P034019GB:BRC

2. Patent application number 0 1 MAY 2003
(The Patent Office will fill in this part) 0310056.7

3. Full name, address and postcode of the or of
each applicant (underline all surnames)

VERNALIS RESEARCH LIMITED
OAKDENE COURT
613 READING ROAD
WINNERSH
WOKINGHAM
RG41 5UA

Patents ADP number (if you know it)

7915184001

If the applicant is a corporate body, give the
country/state of its incorporation

UNITED KINGDOM

4. Title of the invention NEW CHEMICAL COMPOUNDS I

5. Name of your agent (if you have one) Carpmaels & Ransford

"Address for service" in the United Kingdom,
to which all correspondence should be sent
(including the postcode)

43 Bloomsbury Square
London
WC1A 2RA

Patents ADP number (if you know it)

83001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)

8. Is a statement of inventorship and of right
to grant of a patent required in support of
this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an
applicant, or
- c) any named applicant is a corporate body

Yes

See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form -

Description 80

Claim(s) 7

Abstract -

Drawing(s) -

g

10. If you are also filing any of the following, state how many against each item.

Priority documents -

Translations of priority documents -

Statement of inventorship and right to grant of a patent (Patents Form 7/77) -

Request for preliminary examination and search (Patents Form 9/77) -

Request for substantive examination (Patents Form 10/77) -

Any other documents (please specify) -

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

Carpmaels & Ransford

Carpmaels & Ransford

1st May 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr. Bruce R. Cockerton

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

NEW CHEMICAL COMPOUNDS - I

The present invention relates primarily to the use of azetidine-1-carboxamides in the treatment of disorders mediated by the cannabinoid CB₁ receptor, particularly to the
5 treatment of obesity and other eating disorders associated with excessive food intake.

It has been recognised that obesity is a disease process influenced by environmental factors in which the traditional weight loss methods of dieting and exercise need to be supplemented by therapeutic products (S. Parker, "Obesity: Trends and Treatments", Scrip Reports, PJB
10 Publications Ltd, 1996).

Whether someone is classified as overweight or obese is generally determined on the basis of their body mass index (BMI) which is calculated by dividing body weight (kg) by height squared (m²). Thus, the units of BMI are kg/m² and it is possible to calculate the BMI
15 range associated with minimum mortality in each decade of life. Overweight is defined as a BMI in the range 25-30 kg/m², and obesity as a BMI greater than 30 kg/m². There are problems with this definition in that it does not take into account the proportion of body mass that is muscle in relation to fat (adipose tissue). To account for this, obesity can also be defined on the basis of body fat content: greater than 25% and 30% in males and
20 females, respectively.

As the BMI increases there is an increased risk of death from a variety of causes that is independent of other risk factors. The most common diseases with obesity are cardiovascular disease (particularly hypertension), diabetes (obesity aggravates the
25 development of diabetes), gall bladder disease (particularly cancer) and diseases of reproduction. Research has shown that even a modest reduction in body weight can correspond to a significant reduction in the risk of developing coronary heart disease.

Compounds marketed as anti-obesity agents include Orlistat (Reductil®) and Sibutramine.
30 Orlistat (a lipase inhibitor) inhibits fat absorption directly and tends to produce a high incidence of unpleasant (though relatively harmless) side-effects such as diarrhoea. Sibutramine (a mixed 5-HT/noradrenaline reuptake inhibitor) can increase blood pressure and heart rate in some patients. The serotonin releaser/reuptake inhibitors fenfluramine

(Pondimin®) and dexfenfluramine (Redux™) have been reported to decrease food intake and body weight over a prolonged period (greater than 6 months). However, both products were withdrawn after reports of preliminary evidence of heart valve abnormalities associated with their use. There is therefore a need for the development of a safer anti-
 5 obesity agent.

There now exists extensive pre-clinical and clinical data supporting the use of CB₁ receptor antagonists / inverse agonists for the treatment of obesity.

10 Preparations of marijuana (*Cannabis sativa*) have been used for over 5000 years for both medicinal and recreational purposes. The major psychoactive ingredient of marijuana has been identified as Δ^9 -tetrahydrocannabinol (Δ^9 -THC), one of a member of over 60 related cannabinoid compounds isolated from this plant. It has been demonstrated that Δ^9 -THC exerts its effects via agonist interaction with cannabinoid (CB) receptors. So far, two
 15 cannabinoid receptor subtypes have been characterised (CB₁ and CB₂). The CB₁ receptor subtype is found predominantly in the central nervous system, and to a lesser extent in the peripheral nervous system and various peripheral organs. The CB₂ receptor subtype is found predominantly in lymphoid tissues and cells. To date, three endogenous agonists (endocannabinoids) have been identified which interact with both CB₁ and CB₂ receptors
 20 (anandamide, 2-arachidonyl glycerol and noladin ether).

Genetically obese rats and mice exhibit markedly elevated endocannabinoid levels in brain regions associated with ingestive behaviour (Di Marzo et al. 2001 Nature 410: 822 - 825). Furthermore, increased levels of endocannabinoids are observed upon the fasting of
 25 normal, lean animals (Kirkham et al., British Journal of Pharmacology 2002, 136(4) 550-557). Exogenous application of endocannabinoids leads to the same physiological effects observed with Δ^9 -THC treatment, including appetite stimulation (Jamshida et al., British Journal of Pharmacology 2001, 134: 1151-1154), analgesia, hypolocomotion, hypothermia, and catalepsy.

30

CB₁ (CB₁^{-/-}) and CB₂ (CB₂^{-/-}) receptor knockout mice have been used to elucidate the specific role of the two cannabinoid receptor subtypes. Furthermore, for ligands such as Δ^9 -THC which act as agonists at both receptors, these mice have allowed identification of

which receptor subtype is mediating specific physiological effects. $CB_1^{-/-}$, but not $CB_2^{-/-}$, mice are resistant to the behavioural effects of agonists such as Δ^9 -THC. $CB_1^{-/-}$ animals have also been shown to be resistant to both the body weight gain associated with chronic high fat diet exposure, and the appetite-stimulating effects of acute food deprivation.

5

These findings suggest a clear role for both endogenous and exogenous cannabinoid receptor agonists in increasing food intake and body weight *via* selective activation of the CB_1 receptor subtype.

- 10 The therapeutic potential for cannabinoid receptor ligands has been extensively reviewed (Exp. Opin. Ther. Pat. 1998, 8, 301-313; Exp. Opin. Ther. Pat. 2000, 10, 1529-1538; Trends in Pharm. Sci. 2000, 21, 218-224; Exp. Opin. Ther. Pat. 2002, 12(10), 1475-1489).

- At least one compound (SR-141716A) characterised as a CB_1 receptor antagonist / inverse
15 agonist is known to be in clinical trials for the treatment of obesity.


- WO 00/15609, WO 01/64632, WO 01/64633 and WO 01/64634 disclose azetidine derivatives as CB_1 receptor antagonists. WO 02/28346 discloses the association of an azetidine derivative as a CB_1 receptor antagonist, and sibutramine, for the treatment of
20 obesity.

- There remains a medical need for low molecular weight CB_1 receptor antagonists / inverse agonists with pharmacokinetic and pharmacodynamic properties making them suitable for use as pharmaceutical agents. There also remains a medical need for new treatments of
25 disorders mediated by the CB_1 receptor, particularly eating disorders, and particularly obesity. The object of the present invention is to provide such pharmaceutical agents and treatments.

- It has now been found that certain azetidine-1-carboxamides show unexpected efficacy as
30 anti-obesity agents. Compounds of this general formula were previously described in WO-A-99/37612 for the treatment of anxiety and epilepsy. These azetidine-1-carboxamides have been shown to selectively bind to the CB_1 receptor subtype with high affinity. Such compounds have been shown to dose-dependently block the effects of an exogenously

applied cannabinoid receptor agonist (eg Δ^9 -THC) in mice. Furthermore, such compounds have been shown to reduce food intake and body weight gain in both rat and mouse models of feeding behaviour.

- 5 According to the present invention, there is provided a compound of formula (I)



wherein:

R^1 and R^2 are independently selected from aryl; and

R^3 is hydrogen or alkyl;

- 10 or a pharmaceutically acceptable salt or prodrug thereof,
wherein at least one of R^1 and R^2 has a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [-CH-O-] group.

The active compounds of formula (I) are antagonists and/or inverse agonists at the
15 cannabinoid-1 (CB_1) receptor and are useful for the treatment, prevention and suppression of diseases mediated by the CB_1 receptor. The invention is concerned with the use of these compounds to selectively antagonise the CB_1 receptor and, as such, in the treatment of obesity and other disorders.

- 20 Reference in the present specification to an "alkyl" group means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl (including allyl) or alkynyl (including propargyl)) hydrocarbyl radical. Where cyclic or acyclic the alkyl group is preferably C_1 to C_{12} , more preferably C_1 to C_8 (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, pentyl, isopentyl, hexyl, heptyl, octyl). It will be appreciated therefore that
25 the term "alkyl" as used herein includes alkyl (branched or unbranched), alkenyl (branched or unbranched), alkynyl (branched or unbranched), cycloalkyl, cycloalkenyl and cycloalkynyl. A cyclic alkyl group may also be a mono-bridged or multiply-bridged cyclic alkyl group. In a preferred embodiment, a cyclic alkyl group is preferably C_3 to C_{12} , more preferably C_5 to C_8 and an acyclic alkyl group is preferably C_1 to C_{10} , more preferably C_1 to C_6 , more preferably

methyl, ethyl, propyl (n-propyl or isopropyl), butyl (n-butyl, isobutyl, tertiarybutyl or sec-butyl) or pentyl (including n-pentyl and iso-pentyl), more preferably methyl.

- As used herein, the term "lower alkyl" means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical wherein said cyclic lower alkyl group is C₅, C₆ or C₇, and wherein said acyclic lower alkyl group is C₁, C₂, C₃ or C₄. It will be appreciated therefore that the term "lower alkyl" as used herein includes lower alkyl (branched or unbranched), lower alkenyl (branched or unbranched), lower alkynyl (branched or unbranched), cycloloweralkyl, cycloloweralkenyl and cycloloweralkynyl.
- 10 Preferably, a lower alkyl group is preferably selected from methyl, ethyl, propyl (n-propyl or isopropyl) or butyl (n-butyl, isobutyl, tertiary-butyl or sec-butyl), more preferably methyl.

Reference in the present specification to an "aryl" group means a mono or bicyclic aromatic group, such as phenyl or naphthyl, and preferably a mono-cyclic aromatic group.

15

Reference in the present specification to a "heteroaryl" group means an aromatic group containing one or more heteroatoms, preferably 1, 2 or 3 heteroatoms, preferably 1 or 2 heteroatoms. Preferably the heteroatoms are selected from O, S and N, preferably from O and N. Preferably the heteroaryl group comprises 5 or 6-membered ring systems. The heteroaryl group is preferably a monocyclic or bicyclic ring system, preferably monocyclic. Examples include thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl and isobenzofuryl.

25 Reference in the present specification to a non-aromatic heterocyclic group is to a saturated or partially unsaturated 4, 5, 6 or 7-membered ring containing 1, 2 or 3 heteroatoms selected from N, O and S, preferably 1 or 2 heteroatoms, preferably selected from N and O. Examples include piperidinyl, morpholinyl, piperazinyl and pyrrolidinyl.

30 The alkyl, aryl and heteroaryl groups may be substituted or unsubstituted. In one embodiment, only the alkyl, aryl and heteroaryl groups defined herein as R¹ to R¹⁶ may be substituted. Where R⁷ and R⁸ together form a 5 or 6-membered ring, the ring may be substituted or

alkyl

5

haloalkyl

oxygen containing groups such as

10

alcohols

(e.g. hydroxy, hydroxyalkyl, (aryl)(hydroxy)alkyl),

ethers

(e.g. alkoxy, alkoxyalkyl, aryloxyalkyl),

aldehydes

(e.g. carboxaldehyde),

ketones

(e.g. alkylcarbonyl, alkylcarbonylalkyl, arylcarbonyl, arylalkylcarbonyl, arylcarbonylalkyl),

15 acids (e.g. carboxy, carboxyalkyl),

acid derivatives such as esters

(e.g. **alkoxycarbonyl**, **alkoxycarbonylalkyl**,
alkylcarbonyloxy, **alkylcarbonyloxyalkyl**)

and amides

20 (e.g. aminocarbonyl, mono- or dialkylaminocarbonyl, aminocarbonylalkyl, mono- or dialkylaminocarbonylalkyl, arylaminocarbonyl);

20

nitrogen containing groups such as

amines

(e.g. amino, mono- or dialkylamino, aminoalkyl, mono- or dialkylaminoalkyl),

25

azides,

nitriles

(e.g. cyano, cyanoalkyl),

nitro;

sulphur containing groups such as

30 thiols, thioethers, sulphoxides and sulphones

30

(e.g. alkylthio, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsulfinylalkyl,

alkylsulfonylalkyl, arylthio, arylsulfinyl, arylsulfonyl, arylthioalkyl, arylsulfinylalkyl, arylsulfonylalkyl);

and heterocyclic groups containing one or more, preferably one, heteroatom,

(e.g. thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl,
 5 thiazolyl, isothiazolyl, oxazolyl, pyrrolidinyl,
 pyrrolinyl, imidazolidinyl, imidazoliny, pyrazolidinyl,
 tetrahydrofuranyl, pyranyl, pyronyl, pyridyl, pyrazinyl,
 pyridazinyl, piperidyl, piperazinyl, morpholinyl,
 thionaphthyl, benzofuranyl, isobenzofuryl, indolyl,
 10 oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-
 azaindolyl, isoindazolyl, benzopyranyl, coumarinyl,
 isocoumarinyl, quinolyl, isoquinolyl, naphthridinyl,
 cinnolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl,
 quinoxadinyl, chromenyl, chromanyl, isochromanyl
 15 and carbolinyl).

Where an aryl group is phenyl, the phenyl may be substituted by adjacent substituents forming a 5 or 6 membered saturated ring optionally containing 1 or 2 heteroatoms, preferably selected from N, O and S, preferably from N and O. Where the saturated ring
 20 contains 2 nitrogen atoms, the ring is preferably a 6-membered ring. Where the saturated ring contains 2 oxygen atoms, the ring may be a 5- or 6-membered ring. Examples include 2,3-dihydrobenzo[b]furan-7-yl, 2,3-dihydrobenzo[b]thiophen-6-yl, 1,2,3,4-tetrahydronaphthalen-5-yl, 2,3-dihydrobenzo[1,4]dioxin-6-yl and 1,2,3,4-tetrahydroisoquinolin-8-yl.

25 Preferred substituents include alkyl (including haloalkyl), alkoxy (including haloalkoxy), aryl, nitrile or halo. Preferred halogen-containing groups include trifluoromethyl.


As used herein, the term "alkoxy" means alkyl-O- and "alkoyl" means alkyl-CO-.

30 As used herein, the term "halogen" means a fluorine, chlorine, bromine or iodine radical, preferably a fluorine or chlorine radical.

The compounds of formula (I) may exist in a number of diastereomeric and/or enantiomeric forms. Unless otherwise stated, reference in the present specification to “a compound of formula (I)” is a reference to all stereoisomeric forms of the compound and includes a reference to the unseparated stereoisomers in a mixture, racemic or non-racemic, and to each stereoisomer in its pure form.

In the compounds of formula (I), preferably R^1 and R^2 are independently selected from substituted or unsubstituted phenyl or naphthyl (preferably phenyl), more preferably substituted phenyl or naphthyl (preferably phenyl), more preferably phenyl or naphthyl (preferably phenyl) having 1 to 3 substituents and most preferably phenyl or naphthyl (preferably phenyl) having 1 or 2 substituents. In one embodiment the substituent groups are selected from halogen and haloalkyl (particularly trifluoromethyl). Preferably R^1 and R^2 are selected from mono-cyclic aromatic groups.

In a preferred embodiment of the compounds of formula (I), R^1 and R^2 are independently selected from a group of formula:



wherein R^4 , R^5 and R^6 are independently selected from hydrogen, halo, alkyl (including haloalkyl), thioalkyl, alkoxy (including haloalkoxy), alkylsulfonyl, amino, mono- and di-alkyl amino, mono- and di-aryl amino, alkylaryl amino, $NR^{14}C(O)R^{15}$, $NR^{14}SO_2R^{16}$, $COOR^{15}$, $OC(O)R^{16}$, $CONR^7R^8$ and $SO_2NR^7R^8$, wherein R^7 and R^8 are independently selected from hydrogen and alkyl or may form a 5 or 6 membered ring optionally containing 1 or 2 additional heteroatoms selected from N, O and S; and wherein R^{14} is selected from H and lower alkyl (preferably H), R^{15} is selected from H, alkyl, aryl and heteroaryl (preferably alkyl, preferably lower alkyl) and R^{16} is selected from alkyl, aryl and heteroaryl (preferably alkyl, preferably lower alkyl). The groups R^1 and R^2 may be the same or different, and in one embodiment are different.

Where R^4 , R^5 and R^6 are selected from halo, the halo group is preferably fluoro, chloro, bromo or iodo, preferably chloro or bromo. Where R^4 , R^5 and R^6 are selected from alkyl, thioalkyl, alkoxy and alkylsulfonyl, the alkyl is preferably selected from lower alkyl, and preferably from methyl and ethyl, preferably methyl. Where R^4 , R^5 and R^6 are selected from haloalkyl, the alkyl is preferably methyl, and the R^4 , R^5 or R^6 group is preferably trifluoromethyl. Where R^4 , R^5 and R^6 are selected from haloalkoxy, the alkyl is preferably methyl and the R^4 , R^5 or R^6 group is preferably selected from trifluoromethoxy or difluoromethoxy, preferably difluoromethoxy. Preferably one or two of R^4 , R^5 and R^6 are hydrogen. At least one of the R^1 and R^2 groups has a non-hydrogen substituent in the ortho-position(s). The R^1 or R^2 groups may independently have one or two non-hydrogen substituents in the ortho position(s) relative to the point of attachment to the $[-CH-O-]$ group. Preferred ortho-substituents include halo and haloalkyl, as described herein. Particularly preferred ortho-substituents are chloro and trifluoromethyl, particularly trifluoromethyl.

15

Where R^7 and R^8 form a 5- or 6-membered ring, the ring is preferably 6-membered, and is preferably saturated or partially saturated, preferably saturated. Where the ring contains additional heteroatoms, these are preferably selected from N and O. Preferably there are 0 or 1 additional heteroatoms.

20

In the compounds of formula I, R^3 is selected from hydrogen or alkyl, preferably alkyl.

Where R^3 is selected from alkyl, preferably R^3 is lower alkyl, and preferably methyl, ethyl, propyl and butyl as described above. The alkyl group may be substituted or unsubstituted, and in one embodiment is substituted. One or two substituent groups may be present, preferably one substituent group. Preferred substituents are those referred to hereinabove, particularly hydroxy, alkoxy, thioalkyl, amino, mono- and dialkyl amino, alkoxycarbonyl, aryl (preferably phenyl), and heterocyclic groups including both heteroaryl and non-aromatic heterocyclic groups. Where R^3 is an acyclic alkyl group, it may be substituted by a cyclic alkyl group; and where R^3 is a cyclic alkyl group it may be substituted by an acyclic alkyl group. Where the substituent group is heteroaryl, the heteroaryl preferably is a 5- or 6-membered ring containing one or more N, O or S atoms, and preferred groups include thiophenyl, furanyl, isoxazolyl, thiazolyl and benzothiophenyl. Other preferred substituent


25

30

groups include dihydrobenzofuranyl, dihydrobenzodioxinyl, tetrahydrofuranyl, pyrrolidinyl, oxopyrrolindyl and benzodioxolyl.

In one embodiment, R³ is selected from :

5



wherein n is 0 or 1;

m is 0, 1, 2 or 3;

R⁹, R¹⁰, R¹¹ and R¹² are selected from hydrogen, alkyl (preferably lower alkyl), hydroxy, alkoxy (preferably lower alkoxy), thioalkyl (preferably thio lower alkyl), amino, mono- and di-alkyl amino (preferably lower alkyl amino), alkoxycarbonyl (preferably lower alkoxy carbonyl) and R¹³;

wherein R¹³ is selected from aryl, heteroaryl and non-aromatic heterocyclic optionally substituted by one or more (preferably 1 or 2, preferably 1) groups preferably selected from alkyl (preferably lower alkyl, preferably methyl), halogen (preferably fluoro, chloro and bromo), alkoxy (preferably lower alkoxy, preferably methoxy), oxo, aryl, heteroaryl and non-aromatic heterocycle.

Preferably, m is 0 or 1 or 2, preferably 0 or 1, and preferably 0.

20

Preferably, n is 0.

In one embodiment, at least one and more preferably two of R¹⁰, R¹¹ and R¹² are selected from hydrogen. In a further embodiment, at least one and more preferably at least two of R¹⁰, R¹¹ and R¹² are selected from methyl.

25

In a further embodiment, R³ is selected from cyclic alkyl, including cyclopentyl, cyclohexyl, norbornanyl and adamantyl, preferably cyclopentyl and cyclohexyl.

Preferred R³ groups are tertiary butyl, sec-butyl, isobutyl, isopropyl, n-propyl and ethyl, particularly tertiary butyl, isobutyl, sec-butyl and isopropyl, and particularly tertiary butyl.

30

Preferred compounds are as follows:

3-(2,4,4'-trichlorobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(ethyl propionate-2-yl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(2-thiophen-2-yl ethyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-[ethyl 4-(methylthio)butyrate-2-yl]azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(cyclopropylmethyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(2,3-dihydrobenzofuran-5-yl-methyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(2,5-dimethylfuran-3-yl-methyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(2,3-Dihydro-benzo[1,4]dioxin-2-yl-methyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(5-methyl-isoxazol-3-yl-methyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-[(R)-sec-butyl]azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(2-bromothiophen-3-yl-methyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-[(S)-sec-butyl]azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(thiophen-3-yl-methyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(2-methoxyphenylmethyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(2-furanylmethyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(3-ethoxypropyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(2-tetrahydrofuranylmethyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(exo-2-norbornanyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(1-phenylpropyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-[(R)-a-methylbenzyl]azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-[(R)-1-(3-methoxyphenyl)ethyl]azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-[(S)-1-(3-methoxyphenyl)ethyl]azetidine-1-carboxamide
 3-(4,4'-dichlorobenzhydryloxy)-N-(1-adamantyl)azetidine-1-carboxamide
 3-(4,4'-dichlorobenzhydryloxy)-N-(benzo[b]thiophen-2-yl-methyl)azetidine-1-carboxamide
 3-(2,2'-dichlorobenzhydryloxy)-N-(1-adamantyl)azetidine-1-carboxamide
 3-(4,4'-dibromobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide
 3-(4,4'-dibromobenzhydryloxy)-N-(1-adamantyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(n-propyl)azetidine-1-carboxamide

- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(n-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(ethyl propionate-3-yl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(ethyl 3-phenylpropionate-2-yl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(ethyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-[(S)-a-methyl-benzyl]azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(2,2,4-trimethylpent-4-yl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(cyclopentyl)azetidine-1-carboxamide
- 3-(2,4'-dichlorobenzhydryloxy)-N-(2,2,4-trimethylpent-4-yl)azetidine-1-carboxamide
- 3-(2,4'-dichlorobenzhydryloxy)-N-(2-methylbut-2-yl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-2'-fluoro-4'-bromobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(benzyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(benzyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide

- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(benzyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-N-(benzyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(tert-amyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methoxybenzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methoxybenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(allyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(cyclohexyl)azetidine-1-

carboxamide

3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(allyl)azetidine-1-carboxamide

3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide

3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide

3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-[(S)-a-methylbenzyl]azetidine-1-carboxamide

3-[2-(trifluoromethyl)-2'-fluoro-4'-(1-piperidinyloxomethyl)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide

3-[2-(trifluoromethyl)-2'-fluorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide, and

3-[(S*)-2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide

Particularly preferred compounds are as follows:

3-(2,4,4'-trichlorobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2-thiophen-2-yl ethyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(cyclopropylmethyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2,3-dihydrobenzofuran-5-yl-methyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2,5-dimethylfuran-3-yl-methyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2,3-Dihydro-benzo[1,4]dioxin-2-yl-methyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(5-methyl-isoxazol-3-yl-methyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-[(R)-sec-butyl]azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2-bromothiophen-3-yl-methyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-[(S)-sec-butyl]azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(thiophen-3-yl-methyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2-methoxyphenylmethyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2-furanylmethyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(3-ethoxypropyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2-tetrahydrofuranylmethyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(exo-2-norbornanyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(1-phenylpropyl)azetidine-1-carboxamide

- 3-(2,4'-dichlorobenzhydryloxy)-N-[(R)-a-methylbenzyl]azetidine-1-carboxamide
- 3-(2,4'-dichlorobenzhydryloxy)-N-[(R)-1-(3-methoxyphenyl)ethyl]azetidine-1-carboxamide
- 3-(2,4'-dichlorobenzhydryloxy)-N-[(S)-1-(3-methoxyphenyl)ethyl]azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(n-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(ethyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-[(S)-a-methyl-benzyl]azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(2,2,4-trimethylpent-4-yl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(cyclopentyl)azetidine-1-carboxamide
- 3-(2,4'-dichlorobenzhydryloxy)-N-(2,2,4-trimethylpent-4-yl)azetidine-1-carboxamide
- 3-(2,4'-dichlorobenzhydryloxy)-N-(2-methylbut-2-yl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-2'-fluoro-4'-bromobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(benzyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(benzyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(benzyl)azetidine-1-carboxamide

- 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-N-(benzyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(tert-amyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methoxybenzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methoxybenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(allyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(allyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide

3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-[(S)-a-methylbenzyl]azetidine-1-carboxamide

3-[2-(trifluoromethyl)-2'-fluoro-4'-(1-piperidinyloxomethyl)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide

3-[2-(trifluoromethyl)-2'-fluorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide, and
3-[(S*)-2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide.

According to a further aspect of the invention, there is provided for use in therapy a compound of formula (I).

- 5 According to a further aspect of the invention, there is provided the use of a compound of formula (I) in the manufacture of a medicament for the treatment of a disorder mediated by CB₁ receptors.

10 According to a further aspect of the present invention there is provided a method of treatment of a disorder mediated by CB₁ receptors comprising administration to a subject in need of such treatment an effective dose of the compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof.

15 The disorders mediated by CB₁ receptors are selected from psychosis, memory deficit, cognitive disorders, attention deficit disorder, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular injuries, head trauma, anxiety disorders, depression, stress, epilepsy, dementia, dystonia, Alzheimer's disease, Huntingdon's disease, Tourette's syndrome, ischaemia, pain, Parkinson's disease, schizophrenia,
20 substance abuse disorders especially relating to nicotine, alcohol, and opiates, smoking cessation, treatment of nicotine dependance and/or treatment of symptoms of nicotine withdrawal, gastrointestinal disorders (such as dysfunction of gastrointestinal motility or diarrhoea), obesity and other eating disorders associated with excessive food intake, and associated health complications including non-insulin dependant diabetes mellitus.

25

The present invention is particularly directed to psychosis, memory deficit, cognitive disorders, attention deficit disorder, migraine, anxiety disorders, stress, epilepsy,

Parkinson's disease, schizophrenia, substance abuse disorders especially relating to nicotine, alcohol, and opiates, smoking cessation, treatment of nicotine dependance and/or treatment of symptoms of nicotine withdrawal, gastrointestinal disorders (such as dysfunction of gastrointestinal motility or diarrhoea), obesity and other eating disorders
5 associated with excessive food intake, and associated health complications including non-insulin dependant diabetes mellitus.

The present invention is more particularly directed to disorders selected from psychosis, schizophrenia, cognitive disorders, attention deficit disorder, smoking cessation,
10 gastrointestinal disorders (such as dysfunction of gastrointestinal motility or diarrhoea), obesity and other eating disorders associated with excessive food intake (including bulimia and compulsive eating disorder) and associated health complications including non-insulin dependant diabetes mellitus. The present invention is particularly directed to obesity and other eating disorders associated with excessive food intake and associated health
15 complications including non-insulin dependant diabetes mellitus, and particularly to obesity and other eating disorders associated with excessive food intake, and especially to obesity.

In an alternative embodiment, the present invention is directed to substance abuse
20 disorders especially relating to nicotine, alcohol, and opiates, smoking cessation, treatment of nicotine dependance and/or treatment of symptoms of nicotine withdrawal, and particularly to smoking cessation and the facilitation thereof.

In a further alternative embodiment, the present invention is directed to gastrointestinal
25 disorders (such as dysfunction of gastrointestinal motility or diarrhoea).

In a further alternative embodiment, the present invention is directed to the treatment of Parkinson's Disease.

30 The present invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject.

As used herein, the term "treatment" as used herein includes prophylactic treatment.

- As used herein, the term "prodrug" means any pharmaceutically acceptable prodrug of the compound of formula (I). For example, the compound of formula (I) may be prepared in a prodrug form wherein a free -OH group is derivatised (for example, via an ester, amide or phosphate bond) with a suitable group (the group may contain, for example, an alkyl, aryl, phosphate, sugar, amine, glycol, sulfonate or acid function) which is suitably labile so as it will be removed / cleaved (eg. by hydrolysis) to reveal the compound of formula (I) sometime after administration or when exposed to the desired biological environment.
- 10 As used herein, the term "pharmaceutically acceptable salt" means any pharmaceutically acceptable salt of the compound of formula (I). Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pantoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like. Particularly preferred are hydrochloric, hydrobromic, phosphoric, sulfuric and methanesulfonic acids, and most particularly preferred is the methanesulfonate salt. Acceptable base salts include alkali metal (e.g. sodium, potassium), alkaline earth metal (e.g. calcium, magnesium) and
- 20 aluminium salts.

The compound of formula (I) may be used in combination with one or more additional drugs useful in the treatment of the disorders mentioned above, the components being in the same formulation or in separate formulations for administration simultaneously or


25 sequentially.

Compounds of formula (I) may be prepared according to the reaction scheme (where P is a nitrogen protecting group). R^1 , R^2 , and R^3 are as previously described. The ether (IV) may be formed by reaction of the azetidinol (II) with a benzhydrol (III, $X = OH$) with removal of

30 water (for example azeotropic removal of water under standard Dean-Stark conditions). The ether (IV) may also be formed by reaction of the azetidinol (II) with a benzhydryl group substituted with a suitable leaving-group (III, $X = Cl, Br, I, mesylate, tosylate$) and a strong base such as sodium hydride. Formation of the azetidine (V) may be achieved by reaction of

(IV) with a suitable nitrogen deprotection agent. For example, if P is a benzhydryl group, then deprotection may be carried out by treatment with 1-chloroethyl chloroformate followed by treatment with methanol. The deprotected azetidine (V) can be isolated directly as the hydrochloride salt or, upon basification, as the free-base. The urea (I) can be formed by
 5 reaction of azetidine (V) with an N-alkyl isocyanate, or an N-alkyl carbamoyl chloride and a base such as triethylamine or potassium carbonate. Alternatively, the urea may be prepared directly from the protected azetidine (IV) without isolation of the intermediate azetidine (V). For example, when P is a benzhydryl group, azetidine (IV) may be treated with phosgene followed by an amine, R^3NH_2 , to give urea (I) directly. Azetidine (V) may also be converted
 10 to the corresponding carbamoyl chloride (VI) by treatment with, for example, triphosgene. This intermediate carbamoyl chloride (VI) may be reacted with an amine, R^3NH_2 , to give the urea (I).

Reaction Scheme



15

The invention further provides a pharmaceutical composition comprising an effective amount of the compound of formula (I) in combination with a pharmaceutically acceptable carrier or excipient and a method of making such a composition comprising combining an effective
 20 amount of the compound of formula (I) with a pharmaceutically acceptable carrier or excipient.

To further increase efficacy, the composition may contain components such as dextrans or cyclodextrins or ether derivatives thereof, which aid stability and dispersion, and decrease metabolism of the active ingredient.

5

For compositions in which the pharmaceutically acceptable carrier comprises a cyclodextrin or an ether derivative thereof, the active ingredient is intimately mixed with an aqueous solution of the cyclodextrin or ether derivative thereof, with optional addition of further pharmaceutically acceptable ingredients before, during or after said mixing. The
10 thus obtained solution is optionally lyophilized, and the lyophilized residue is optionally reconstituted with water.

In an embodiment of the present invention, the composition further comprises a buffer system, an isotonizing agent and water.

15

Compounds of formula (I) may be administered in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use including transmucosal and transdermal use, for example a cream, ointment, gel, aqueous or oil solution or suspension, salve, patch or plaster; for nasal use, for example a snuff, nasal spray or nasal
20 drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example a finely divided powder or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oil solution or suspension. In general the above compositions may be prepared in a conventional manner
25 using conventional excipients, using standard techniques well known to those skilled in the art of pharmacy. Preferably, the compound is administered orally.

For oral administration, the compounds of formula (I) will generally be provided in the form of tablets or capsules or as an aqueous solution or suspension.

30

Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert

diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as
5 glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.

Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

10

For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of formula (I) will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions may include suspending agents such as
15 cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.

It will be appreciated that the dosage levels used may vary over quite a wide range depending
20 upon the compound used, the severity of the symptoms exhibited by the patient and the patient's body weight.

The invention will now be described in detail with reference to the following pharmacological examples. It will be appreciated that the examples are intended to
25 illustrate and not to limit the scope of the present invention.

EXPERIMENTAL

Assay Procedures

30

Binding to CB₁ receptors

The binding of compounds of Formula I to recombinant human CB₁ receptors was determined *in vitro* by standard methods, with reference to the procedure described by

Rinaldi-Carmona *et al.* (Rinaldi-Carmona, M., Pialot, F., Congy, C., Redon, E., Barth, F., Bachy, A., Breliere, J. C., Soubre, P., LeFur, G., *Life Sci.* 1996, 58(15), 1239-1247). Membranes were prepared from HEK293 cells expressing recombinant hCB₁ receptors. Binding assays are performed in a total volume of 250 μ L, containing [³H]-SR-141716A (1 nM final concentration), membranes and test compound. Non-specific binding is determined using CP55,940 (10 μ M). Serial dilutions are performed starting from test compounds as 10 mM solutions in DMSO. Compounds are tested over the concentration range 10⁻¹⁰ M to 10⁻⁵ M. K_i values are calculated from IC₅₀ values using the Cheng-Prusoff equation.

10 The thus-determined activity of compounds of formula (I) is shown in Table 1.

Table 1

Example	K _i (hCB ₁) nM
1	4.7
4	4.5
28	80
30	19
81	2.3
94	1.3
139	0.6
140	27

15

Blockade of Δ^9 -THC induced hypolocomotion in mice

The *in vivo* activity of compounds of formula (1) was assayed for ability to antagonise the reduction in locomotor behaviour induced by acute systemic administration of Δ^9 -THC in male C57Bl/6 mice. The procedure was as follows.

20

Test compounds are assessed following acute oral or intraperitoneal administration at a dose of 30 mg/kg. Each study utilises a between-subjects design (typically n=8) and compares the effects of doses of the test agent to those of vehicle and a positive control.

The route of test compound administration, drug volume and injection-test-interval are dependent upon the compounds used. 10 min before testing, a 3 mg/kg dose Δ^9 -THC (or vehicle) is administered to mice by the i.p. route. Automated boxes (AM-1052 activity monitors, Benwick Electronics, Linton Instrumentation) are used to record photocell beam breaks as a measure of locomotor activity. The light beams are arranged on a 7 by 4 matrix on a metal grid. 16 grids are connected in series and Perspex boxes, 20 (width) x 40 (length) x 20 (height) cm, with a flat perforated, Perspex lid are placed in each grid. Mice are placed singly in Perspex boxes and the recording of activity in all 16 boxes starts simultaneously. The mice are left undisturbed to explore the novel activity monitor boxes for 15 minutes while beam breaks are recorded.

Locomotor activity data are subjected to one-way analysis of variance (ANOVA) with drug treatment as a between-subjects factor. A significant main effect is followed up by the performance of Dunnett's test in order to assess which treatment mean(s) are significantly different from the control mean. Significant differences between the vehicle / Δ^9 -THC group and Test compound / Δ^9 -THC groups are assessed by Newman-Keuls test. All statistical analyses were performed using Statistica Software, Version 6.0 (Statsoft Inc.) and Microsoft Excel 7.0 (Microsoft Corp.).

The thus-determined activity of compounds of formula (I) is shown in Table 2.

Table 2

Example	Active dose (mg/kg), route
1	30, <i>p.o.</i>
4	30, <i>p.o.</i>
81	30, <i>p.o.</i>
94	30, <i>p.o.</i>

Regulation of feeding behaviour

The *in vivo* activity of compounds of formula (1) was assayed for ability to regulate feeding behaviour by measuring food consumption in male food-deprived Lister-hooded rats as follows.

Test compounds are assessed following acute administration. Each study utilises a between-subjects design (typically $n=8$) and compares the effects of doses of the test agent to those of vehicle and a positive control.

- 5 The anorectic drug sibutramine, or the reference CB₁ receptor antagonist, SR141716A, normally serves as a positive control. The route of drug administration, drug volume and injection-test-interval are dependent upon the compounds used. The injection-test-interval is the time between dosing and food re-presentation. Typically, animals are fasted such that at the time of food re-presentation food has been withdrawn for an 18-hour period. Food consumption is assayed at pre-determined time points (typically 1, 2 and 4 hours after administration). Food intake data are subjected to one-way analysis of variance (ANOVA) with drug as a between-subjects factor. A significant main effect is followed up by the performance of Dunnett's test in order to assess which treatment mean(s) are significantly different from the control mean. All statistical analyses were performed using Statistica Software, Version 6.0 (Statsoft Inc.) and Microsoft Excel 7.0 (Microsoft Corp.).

The thus-determined activity of compounds of formula (I) is shown in Table 3.

Table 3

Example	M.E.D (mg/kg), route
1	30, <i>p.o.</i>
4	30, <i>p.o.</i>
81	3, <i>p.o.</i>
94	10, <i>p.o.</i>
139	1, <i>p.o.</i>

Analytical Chemistry Procedures

HPLC

- 25 LC (50/80) refers to elution of a sample through an XTERRA RP18 (50 mm x 4.6 mm) 5 μ m column under gradient conditions. The initial eluent comprises 50% Methanol (pump-A) and 50% of a 10 mM aqueous ammonium acetate solution containing 5% IPA (pump-B) at a flow

rate of 2 mL/min. After 1 min, a gradient is run over 5 min to an end point of 80% pump-A and 20% pump-B, which is isochratically maintained for a further 3 min. UV peak detection is generally carried out at a wavelength of 220 nm.

- 5 LC (80/20) refers to elution of a sample through an XTERRA RP18 (50 mm x 4.6 mm) 5 μ m column under isocratic conditions. The eluent comprises 80% Methanol (pump-A) and 20% of a 10 mM aqueous ammonium acetate solution containing 5% IPA (pump-B) at a flow rate of 2 mL/min over a period of 10 minutes. UV peak detection is generally carried out at a wavelength of 220 nm.

10

LC (CHIRAL AD) refers to elution of a sample through a CHIRALPAK AD column (250 mm x 4.6 mm) 10 μ m column under isocratic conditions. The eluent typically comprises 90% *n*-hexane and 10% 2-propanol at flow rate of 1 mL/min over a period of 40 minutes. UV peak detection is generally carried out at a wavelength of 220 nm.

15

¹H NMR

Proton nmr spectra were recorded on a 400 MHz Bruker spectrometer. Solutions were typically prepared in either deuteriochloroform (CDCl₃) or deuterated dimethylsulfoxide (*d*⁶-DMSO) with chemical shifts reported in δ with reference to tetramethylsilane (TMS) as an

- 20 internal standard, and coupling constants reported in Hz.

MS

Mass Spectra were acquired via loop injection on a Waters ZQ Mass Detector equipped with an Electrospray source operated in Positive / Negative Ion switching mode and a cone voltage

- 25 of 25V.

Synthetic Examples

Preparation of 1-benzhydryl-3-azetidinol (1)

- 30 This material was prepared according the method of Anderson and Lok (*J. Org. Chem.*, 1972, 37, 3953 – the disclosure of which is incorporated herein by reference), m.p. 111-112 °C (lit. m.p. 113 °C).

Preparation of 2,4,4'-trichlorobenzhydrol (2)

To a stirred solution of 2,4-dichlorobenzaldehyde (286 mmol) in diethyl ether (500 mL) was added 4-chlorophenylmagnesium bromide (1.0M in diethyl ether, 286 mmol) dropwise at 0 °C over a period of 1 hour. The reaction was allowed to warm to ambient temperature, and stirred for 3 h. The reaction mixture was quenched with saturated ammonium chloride solution (500 mL) and extracted with diethyl ether (2 × 500 mL), the extracts were washed with water and brine, dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by trituration with *iso*-hexane (500 mL) to yield the product as a white solid (60.0 g, 73%). NMR (400MHz, *d*⁶-DMSO) δ_{H} 5.95 (1H, d, *J* 4.5 Hz), 6.23 (1H, d, *J* 4.0 Hz), 7.31 (2H, m), 7.37 (2H, m), 7.47 (1H, dd, *J* 2.5, 8.5 Hz), 7.55 (1H, d, *J* 2.0 Hz), 7.66(1H, d, *J* 8.5 Hz).

Preparation of 1-benzhydryl-3-(2,4,4'-trichlorobenzhydroyloxy)azetidine (3)

A solution of 2,4,4'-trichlorobenzhydrol (2) (174 mmol), *p*-toluenesulfonic acid (174 mmol) and 1-benzhydryl-3-azetidinol (1) (87 mmol) in toluene (700 mL) was heated at reflux under Dean-Stark conditions for 30 minutes. The solution was cooled, washed with sodium hydrogen carbonate (saturated aqueous solution, 700 mL), dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by column chromatography [SiO₂; (10% ethyl acetate:isohexane)] to furnish the product as a yellow oil (22.0 g, 50%). NMR (400MHz, *d*⁶-DMSO) δ_{H} 2.78 (1H, t, *J* 6.5 Hz), 2.84 (1H, t, *J* 6.5 Hz), 3.23 (1H, t, *J* 6.5Hz), 3.31 (1H, t, *J* 6.5Hz), 4.18 (1H, m), 4.39 (1H, s), 5.71 (1H, s), 7.15 (2H, m), 7.24 (4H, m), 7.32 (2H, m), 7.37 (6H, m), 7.47 (1H, m), 7.57 (2H, m).

Preparation of 3-(2,4,4'-trichlorobenzhydroyloxy)azetidine (4)

To a stirred solution of 1-benzhydryl-3-(2,4,4'-trichlorobenzhydroyloxy)azetidine (3) (39 mmol) in dichloromethane (400 mL) was added 1-chloroethylchloroformate (98 mmol) dropwise at 0 °C and the reaction mixture stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo*, then dissolved in methanol (400 mL) and stirred at room temperature for 1 hour. The reaction mixture was concentrated *in vacuo*, then diluted with ethyl acetate (400 mL) and washed with sodium hydroxide (5N, 400 mL), dried (MgSO₄) and concentrated *in vacuo* to furnish a yellow oil. The residue was purified by filtration through silica, eluting with dichloromethane, then [ethyl acetate:methanol:ammonium hydroxide (90:8:2)] to yield a yellow oil (8.0 g, 60%).

NMR (400MHz, DMSO) δ_{H} 3.38 (4H, bd), 4.29 (1H, m), 5.68 (1H, s), 7.32 (2H, m), 7.40 (2H, m), 7.49 (2H, m), 7.50 (1H, m), 7.60 (2H, m).

Example 1. 3-(2,4,4'-trichlorobenzhydryloxy)-*N*-(*tert*-butyl)azetidine-1-

5 carboxamide (5)

To a stirred solution of 3-(2,4,4'-trichlorobenzhydryloxy)azetidine (4) (3 mmol) in dichloromethane (10 mL) was added *tert*-butyl isocyanate (3 mmol) and triethylamine (catalytic amount) and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was eluted through a pre-wetted (CH₂Cl₂) SCX-2 (2 g) cartridge with
10 dichloromethane to yield the desired product as a white foam (424 mg, 33%).

NMR (400MHz, DMSO) δ_{H} 1.20 (9H, s), 3.54 (1H, dd, *J* 4.5, 8.5 Hz), 3.80 (1H, dd, *J* 6.5, 8.5 Hz), 4.29 (1H, m), 5.62 (1H, s), 7.34 (2H, m), 7.42 (2H, m), 7.50 (1H, m), 7.61 (1H, m), 7.64 (1H, s)

LC (50/80) 97.5%, 7.59 min

15 Found: C, 57.19; H, 5.30; N, 6.26, C₁₆H₁₄Cl₃NO requires: C, 57.09; H, 5.25; N, 6.34%

Example 2. 3-(2,4,4'-trichlorobenzhydryloxy)-*N*-(1-hydroxy-2-methylpropan-2-yl)azetidine-1-carboxamide (6)

To a stirred solution of triphosgene (5.5 mmol) in dichloromethane (50 mL) at 0 °C was
20 added a solution of 3-(2,4,4'-trichlorobenzhydryloxy)azetidine (4) (14.6 mmol) and pyridine (16.1 mmol) in dichloromethane (50 mL) over a period of 1 hour. Reaction mixture was warmed to room temperature and stirred for 1 hour. The mixture was purified by filtration through silica, eluting with dichloromethane to yield the carbamoyl chloride intermediate as a dark orange oil. A solution of 'carbamoyl chloride' (2.47 mmol),
25 triethylamine (2.47 mmol) and 2-amino-2-methyl-1-propanol (4.94 mmol) in dichloromethane was stirred at room temperature overnight. The reaction mixture was washed with water, dried (MgSO₄) and purified by chromatography [SiO₂: (1:1 ethyl acetate:isohexane)] to furnish the product as a colourless oil (352 mg, 31%).

NMR (400MHz, *d*⁶-DMSO) δ_{H} 1.13 (6H, s), 3.56(1H, dd, *J* 4.5, 8.5 Hz), 3.80 (1H, dd, *J* 6.5, 8.5 Hz) 4.30 (1H, m), 4.89 (1H, t, *J* 6.0Hz), 5.48 (1H, s), 5.73 (1H, s), 7.34 (2H, m),
30 7.42 (2H, m), 7.51 (1H, m), 7.61 (2H, m)

MS 457 [M+H]⁺

LC (50/80) 99.4%, 6.80 min

Preparation of 2,4'-dichlorobenzhydrol (7)

To a stirred solution of 2,4'-dichlorobenzophenone (239 mmol) in methanol (400 mL) was added sodium borohydride (119 mmol) portionwise at 0°C. Reaction mixture was warmed
 5 to room temperature and stirred for 1 hour, then quenched with water and the methanol was removed under reduced pressure. The residue was diluted with dichloromethane (400 mL) and washed with water and brine, dried (MgSO₄) and concentrated *in vacuo* to yield the product as an orange oil (47.1 g, 78%).

NMR (400MHz, *d*⁶-DMSO) δ_{H} 5.99 (1H, d, *J* 4.5 Hz), 6.16 (1H, d, *J* 4.5 Hz), 7.35 (7H,
 10 m), 7.66 (1H, m).

Preparation of 1-benzhydryl-3-(2,4'-dichlorobenzhydryloxy)azetidine (8)

A solution of 2,4'-dichlorobenzhydrol (7) (178 mmol), *p*-toluenesulphonic acid (198
 15 mmol) and 1-benzhydryl-3-azetidinol (1) (99 mmol) in toluene (500 mL) was heated at reflux in a Dean-Stark apparatus for 40 minutes. The solution was cooled, washed with sodium hydrogen carbonate (saturated aqueous solution, 700 mL), dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by column chromatography [SiO₂; (10% ethyl acetate:isohexane)] to furnish the product as a yellow oil (17.8 g, 38%).

20 NMR (400MHz, *d*⁶-DMSO) δ_{H} 2.78 (1H, t, *J* 6.5 Hz), 2.82 (1H, t, *J* 6.5 Hz), 3.24 (1H, t, *J* 5.5 Hz), 3.28 (1H, t, *J* 5.5 Hz), 4.17 (1H, m), 4.39 (1H, s), 5.74 (1H, s), 7.16 (2H, m), 7.25 (4H, m), 7.32 (3H, m), 7.37 (8H, m), 7.57 (1H, m).

Preparation of 3-(2,4'-dichlorobenzhydryloxy)azetidine hydrochloride (9)

25 To a stirred solution of 1-benzhydryl-3-(2,4'-dichlorobenzhydryloxy)azetidine (8) (38 mmol) in dichloromethane (400 mL) was added 1-chloroethylchloroformate (94 mmol) dropwise at 0 °C and the reaction mixture stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo*, then dissolved in methanol (400 mL) and
 30 stirred at room temperature for 2 hours. The reaction mixture was reduced *in vacuo* and diluted with isohexane (20 mL), diisopropyl ether (200 mL) and methanol (30 mL). Upon stirring, a precipitate formed. Filtration afforded the desired product as a white solid (10.1 g, 77%).

NMR (400MHz, d^6 -DMSO) δ_H 3.86 (2H, br d), 4.02 (2H, br d), 4.43 (1H, quintet, J 6.0 Hz) 5.86 (1H, s), 7.37 (3H, m), 7.44 (4H, m), 7.61 (1H, m), 8.98 (2H, br d).

Example 3: 3-(2,4'-dichlorobenzhydryloxy)-*N*-(ethyl propionate-2-yl)azetidine-1-carboxamide (10)

A solution of 3-(2,4'-dichlorobenzhydryloxy)azetidine hydrochloride (9) (0.58 mmol), ethyl 2-isocyanatopropionate (0.58 mmol) and MP-carbonate (3.10 mmol/g, 1.74 mmol) in dichloromethane (3 mL) was shaken at room temperature overnight. The reaction mixture was eluted through a pre-wetted (CH_2Cl_2) SCX-2 (2 g) cartridge with dichloromethane to yield the desired product as a colourless gum (72 mg, 28%).

NMR (400MHz, d^6 -DMSO) δ_H 1.16 (3H, t, J 7.0 Hz), 1.22 (3H, d, J 7.5 Hz), 3.60 (1H, m), 3.68 (1H, m), 3.87 (1H, m), 3.95 (1H, m), 4.05 (3H, m), 4.36 (1H, m), 5.78 (1H, s), 6.65 (1H, d, J 7.5 Hz), 7.36 (3H, m), 7.41 (4H, m), 7.61 (1H, m).

LC (80/20) 96.5%, 0.80 min

Example 4. 3-(2,4'-dichlorobenzhydryloxy)-*N*-(*tert*-butyl)azetidine-1-carboxamide (11)

This material was prepared, from the corresponding commercially available isocyanate, according to the method for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 1.21 (9H, s), 3.56 (1H, m), 3.63 (1H, m), 3.82 (1H, m), 3.89 (1H, m), 4.27 (1H, m), 5.62 (1H, s), 5.76 (1H, m), 7.42 (6H, m), 7.61 (1H, m)

LC (80/20) 99.5%, 6.84 min

Example 5. 3-(2,4'-dichlorobenzhydryloxy)-*N*-(2-thiophen-2-yl ethyl)azetidine-1-carboxamide (12)

This material was prepared, from the corresponding commercially available isocyanate, according to the method for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 2.87 (2H, t, J 7.0 Hz), 3.18 (2H, m), 3.57 (1H, m), 3.65 (1H, m), 3.83 (1H, m), 3.91 (1H, m), 4.35 (1H, m), 5.77 (1H, s), 6.47 (1H, t, J 5.5 Hz), 6.84 (1H, m), 6.94 (1H, m), 7.30 (1H, m), 7.36 (3H, m), 7.42 (4H, m), 7.60 (1H, m).

LC (80/20) 98.5%, 1.07 min

Example 6. 3-(2,4'-dichlorobenzhydryloxy)-N-(ethyl 3-phenylpropionate-2-yl)azetidine-1-carboxamide (13)

This material was prepared, from the corresponding commercially available isocyanate, according to the method for compound (10).

- 5 NMR (400MHz, d^6 -DMSO) δ_H 2.91 (2H, m), 3.58 (2H, m), 3.87 (1H, m), 4.20 (1H, m), 4.33 (1H, m), 5.76 (1H, s), 6.72 (1H, d, J 8.0 Hz), 7.20 (3H, m), 7.26 (2H, m), 7.36 (3H, m), 7.42 (4H, m), 7.60 (1H, m).

LC (80/20) 99.2%, 1.14 min

10 **Example 7. 3-(2,4'-dichlorobenzhydryloxy)-N-[ethyl 4-(methylthio)butyrate-2-yl]azetidine-1-carboxamide (14)**

This material was prepared, from the corresponding commercially available isocyanate, according to the method for compound (10).

- NMR (400MHz, d^6 -DMSO) δ_H 1.16 (3H, t, J 7.5 Hz), 1.87 (2H, m), 2.03 (3H, s), 2.46 (2H, m), 3.62 (1H, m), 3.70 (1H, m), 3.85-4.00 (2H, m), 4.06 (2H, m), 4.16 (1H, m), 4.37 (1H, m), 5.78 (1H, s), 6.64 (1H, m), 7.37 (3H, m), 7.47 (4H, m), 7.61 (1H, m).

LC (80/20) 99.3%, 0.99 min

20 **Example 8. 3-(2,4'-dichlorobenzhydryloxy)-N-(cyclopropylmethyl)azetidine-1-carboxamide (15)**

3-(2,4'-dichlorobenzhydryloxy)azetidine hydrochloride (9) was converted to the corresponding free-base *via* standard methods.

- To a stirred solution of triphosgene (6.6 mmol) in dichloromethane (50 mL) at 0 °C was added a solution of 'free-base' (17.4 mmol) and pyridine (19.2 mmol) in dichloromethane (50 mL) over a period of 1 hour. Reaction mixture was warmed to room temperature and stirred for 1 hour. The mixture was purified by filtration through silica, eluting with dichloromethane to yield a the carbamoyl chloride as a dark orange oil (5.32 g, 83%) which was used immediately.

- A solution of 'carbamoyl chloride' (0.54 mmol), MP-carbonate (3.10 mmol/g, 1.62 mmol) and (aminomethyl)cyclopropane (0.81 mmol) in dichloromethane was shaken at room temperature overnight. The reaction mixture was eluted through a pre-wetted (CH₂Cl₂) SCX-2 (2 g) cartridge with dichloromethane to yield a colourless gum (51 mg, 22%).

MS 406 [M + H]⁺

LC (80/20) 98.9%, 0.91 min

Example 9. 3-(2,4'-dichlorobenzhydryloxy)-*N*-(2,3-dihydrobenzofuran-5-yl-methyl)azetidine-1-carboxamide (16)

- 5 This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 484 [M + H]⁺

LC (80/20) 89.9%, 1.06 min

10 **Example 10. 3-(2,4'-dichlorobenzhydryloxy)-*N*-(2,5-dimethylfuran-3-yl-methyl)azetidine-1-carboxamide (17)**

This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 460 [M + H]⁺

- 15 LC (80/20) 91.6%, 1.17 min

Example 11. 3-(2,4'-dichlorobenzhydryloxy)-*N*-(2,3-dihydro-benzo[1,4]dioxin-2-yl-methyl)azetidine-1-carboxamide (18)

- 20 This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 500 [M + H]⁺

LC (80/20) 94.5%, 1.34 min

25 **Example 12. 3-(2,4'-dichlorobenzhydryloxy)-*N*-(5-methyl-isoxazol-3-yl-methyl)azetidine-1-carboxamide (19)**

This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 447 [M + H]⁺

LC (80/20) 97.0%, 0.75 min

30

Example 13. 3-(2,4'-dichlorobenzhydryloxy)-*N*-[(*R*)-*sec*-butyl]azetidine-1-carboxamide (20)

This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 408 $[M + H]^+$

LC (80/20) 96.7%, 0.96 min

5

Example 14. 3-(2,4'-dichlorobenzhydryloxy)-N-(2-bromothiophen-3-yl-methyl)azetidine-1-carboxamide (21)

This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

10 MS 527 $[M + H]^+$

LC (80/20) 90.0%, 1.38 min

Example 15. 3-(2,4'-dichlorobenzhydryloxy)-N-[(S)-sec-butyl]azetidine-1-carboxamide (22)

15 This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 408 $[M + H]^+$

LC (80/20) 97.5%, 0.96 min

20 **Example 16. 3-(2,4'-dichlorobenzhydryloxy)-N-(thiophen-3-yl-methyl)azetidine-1-carboxamide (23)**

This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 448 $[M + H]^+$, 446

25 LC (80/20) 98.2%, 1.002 min

Example 17. 3-(2,4'-dichlorobenzhydryloxy)-N-(2-methoxyphenylmethyl)azetidine-1-carboxamide (24)

30 This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 472 $[M + H]^+$

LC (80/20) 97.2%, 1.11 min

Example 18. 3-(2,4'-dichlorobenzhydryloxy)-*N*-(2-furanylmethyl)azetidine-1-carboxamide (25)

This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

5 MS 432 $[M + H]^+$

LC (80/20) 97.0%, 0.88 min

Example 19. 3-(2,4'-dichlorobenzhydryloxy)-*N*-(3-ethoxypropyl)azetidine-1-carboxamide (26)

10 This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 438 $[M + H]^+$

LC (80/20) 99.5%, 0.847 min

15 Example 20. 3-(2,4'-dichlorobenzhydryloxy)-*N*-(2-tetrahydrofuranylmethyl)-azetidine-1-carboxamide (27)

This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 436 $[M + H]^+$

20 LC (80/20) 99.3%, 0.78 min

Example 21. 3-(2,4'-dichlorobenzhydryloxy)-*N*-[3-(2-oxopyrrolidiny)propyl]azetidine-1-carboxamide (28)

25 This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 477 $[M + H]^+$

LC (80/20) 97.7%, 0.68 min

30 Example 22. 3-(2,4'-dichlorobenzhydryloxy)-*N*-(*exo*-2-norbornanyl)azetidine-1-carboxamide (29)

This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 446 $[M + H]^+$

LC (80/20) 97.9%, 1.38 min

Example 23. **3-(2,4'-dichlorobenzhydryloxy)-*N*-(1-phenylpropyl)azetidine-1-carboxamide (30)**

- 5 This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 470 [M + H]⁺

LC (80/20) 89.7%, 1.33 min

- 10 **Example 24.** **3-(2,4'-dichlorobenzhydryloxy)-*N*-[(*R*)- α -methylbenzyl]azetidine-1-carboxamide (31)**

This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 456 [M + H]⁺

- 15 LC (80/20) 92.5%, 1.19 min

Example 25. **3-(2,4'-dichlorobenzhydryloxy)-*N*-[(*R*)-1-(3-methoxyphenyl)ethyl]-azetidine-1-carboxamide (32)**

- 20 This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 486 [M + H]⁺

LC (80/20) 93.6%, 1.17 min

- 25 **Example 26.** **3-(2,4'-dichlorobenzhydryloxy)-*N*-(dimethylaminoethyl)azetidine-1-carboxamide (33)**

This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

MS 423 [M + H]⁺

LC (80/20) 96.8%, 0.71 min

30

Example 27. **3-(2,4'-dichlorobenzhydryloxy)-*N*-[(*S*)-1-(3-methoxyphenyl)ethyl]-azetidine-1-carboxamide (34)**

This material was prepared, from the corresponding commercially available amine, according to the method for compound (15).

LC (80/20) 96.8%, 1.18 min

MS 486 $[M + H]^+$

5

Preparation of 1-benzhydryl-3-(4,4'-dichlorobenzhydryloxy)azetidine (35)

This material was prepared from 1-benzhydryl-3-azetidinol (1) (45.0 mmol) and 4,4'-dichlorobenzhydrol (90.0 mmol) using the procedure described for compound (3) (8.6 g, 40%).

10

NMR (400MHz, d^6 -DMSO) δ_H 2.80 (2H, m), 3.25 (2H, m), 4.13 (1H, t, J 6.0 Hz), 4.39 (1H, s), 5.50 (1H, s), 7.15 (2H, m), 7.25 (4H, m), 7.31-7.40 (12H, m).

LC (50/80) 99.7%, 3.18 min

15 Preparation of 3-(4,4'-dichlorobenzhydryloxy)azetidine (36)

To a stirred solution of 1-benzhydryl-3-(4,4'-dichlorobenzhydryloxy)azetidine (35) (8.4 mmol) in dichloromethane (50 mL) was added 1-chloroethylchloroformate (16.9 mmol) dropwise at 0 °C and the reaction mixture was stirred at reflux for 6 hours. The reaction mixture was cooled to room temperature, concentrated *in vacuo*, then dissolved in methanol (50 mL) and stirred at room temperature for overnight. The reaction mixture was reduced *in vacuo* and triturated with diethyl ether (100 mL) to afford the desired product as a white solid (2.16 g, 74%).

20

NMR (400MHz, d^6 -DMSO) δ_H 3.84 (2H, m), 3.99 (2H, m), 4.39(1H, quintet, J 6.5 Hz), 5.65 (1H, s), 7.37 (4H, m), 7.44 (4H, m).

25 LC (50/80) 98.8%, 4.32 min

Example 28. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(*tert*-butyl)azetidine-1-carboxamide (37)

This material was prepared from 3-(4,4'-dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available isocyanate, using the procedure described for compound (5) (53.0 mg, 45%).

30

NMR (400MHz, d^6 -DMSO) δ_H 1.20 (9H, s), 3.58 (2H, m), 3.83 (2H, m), 4.24 (1H, m), 5.61 (1H, s), 7.39 (8H, m).

LC (50/80) 99.0%, 6.84

Example 29. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(*n*-hexyl)azetidine-1-carboxamide (38)

This material was prepared from 3-(4,4'-dichlorobenzhydryloxy)azetidine (36) and the
5 corresponding commercially available isocyanate, using the procedure described for compound (5).

NMR (400MHz, d^6 -DMSO) δ_H 0.847 (3H, t, J 7.0 Hz), 1.20 – 1.37 (8H, br m), 2.93
2H, q, J 6.5 Hz), 3.56 (2H, m), 3.83 (2H, m), 4.28 (1H, m), 5.55 (1H, s), 6.28 (1H, t, J
5.5 Hz), 7.39 (8H, m).

10 LC (50/80) 97.6%, 8.21 min.

Example 30. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(1-adamantyl)azetidine-1-carboxamide (39)

This material was prepared from 3-(4,4'-dichlorobenzhydryloxy)azetidine (36) and the
15 corresponding commercially available isocyanate, using the procedure described for compound (5).

NMR (400MHz, d^6 -DMSO) δ_H 1.58 (6H, br m), 1.86 (6H, m), 1.97 (3H, br s), 3.57 (2H,
m), 3.83 (2H, m), 4.23 (1H, m), 5.53 (1H, s), 7.33 – 7.42 (8H, m)

LC (50/80) 98.0%, 8.95 min

20

Example 31. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(cyclohexyl)azetidine-1-carboxamide (40)

This material was prepared from 3-(4,4'-dichlorobenzhydryloxy)azetidine (36) and the
25 corresponding commercially available isocyanate, using the procedure described for compound (5).

NMR (400MHz, d^6 -DMSO) δ_H 0.97 – 1.26 (5H, br m), 1.49 – 1.72 (5H, br m), 3.57 (2H,
m), 3.83 (2H, m), 4.27 (1H s), 6.05 (1H, m), 6.34 – 7.45 (8H, m)

LC (50/80) 97.2%, 7.67 min

30 **Example 32. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(3-methylbenzyl)azetidine-1-carboxamide (41)**

This material was prepared from 3-(4,4'-dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available isocyanate, using the procedure described for compound (5).

NMR (400MHz, DMSO) δ_H 2.26 (2H, s), 3.63 (1H, m), 3.89 (1H, m), 4.12 (1H, m), 4.30 (1H, m), 5.76 (1H, s), 7.01 (2H, m), 7.17 (1H, m), 7.38 (5H, m)
LC (50/80) 87.8%, 7.73 min

Example 33. 3-(4,4'-dichlorobenzhydryloxy)-N-(4-methylbenzyl)azetidine-1-carboxamide (42)

10 This material was prepared from 3-(4,4'-dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available isocyanate, using the procedure described for compound (5)

NMR (400MHz, d^6 -DMSO) δ_H 2.26 (3H, s), 3.63 (2H, m), 3.89 (2H, m), 4.11 (2H, m), 4.30 (1H, m), 5.76 (1H, s), 6.85 (1H, m), 7.10 (4H, m), 7.39 (8H, m)

15 LC (50/80) 94.4%, 7.77 min

Example 34. 3-(4,4'-dichlorobenzhydryloxy)-N-(2,4-dichlorobenzyl)azetidine-1-carboxamide (43)

20 This material was prepared from 3-(4,4'-dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available isocyanate, using the procedure described for compound (5).

NMR (400MHz, d^6 -DMSO) δ_H 3.67 (2H, m), 3.94 (2H, m), 4.19 (2H, m), 4.33 (1H, m), 5.58 (1H, s), 6.97 (1H, t, J , 6.0 Hz), 7.30 (1H, m), 7.36 – 7.45 (9H, m), 7.57 (1H, m)

LC (50/80) 97.0%, 8.83 min

25

Example 35. 3-(4,4'-dichlorobenzhydryloxy)-N-(phenethyl)azetidine-1-carboxamide (44)

30 This material was prepared from 3-(4,4'-dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available isocyanate, using the procedure described for compound (5).

NMR (400MHz, d^6 -DMSO) δ_H 2.66 (2H, t, J 7.5 Hz), 3.15 (2H, m), 3.58 (2H, m), 3.84 (2H, m), 4.29 (1H, m), 5.55 (1H, s), 6.42 (1H, t, J 5.5 Hz), 7.18 (3H, m), 7.27 (2H, m), 7.35 – 7.44 (8H, m)

LC (50/80) 90.2%, 7.56 min

Example 36. 3-(4,4'-dichlorobenzhydryloxy)-N-(4-fluorobenzyl)azetidine-1-carboxamide (45)

5 This material was prepared from 3-(4,4'-dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available isocyanate, using the procedure described for compound (5).

NMR (400MHz, d^6 -DMSO) δ_H 3.64 (2H, m), 3.89 (2H, m), 4.14 (2H, m), 4.31 (1H, m), 5.56 (1H, s), 6.91 (1H, t, J 6.0 Hz), 7.11 (2H, m), 7.25 (2H, m), 7.35 – 7.44 (8H, m)

10 LC (50/80) 96.9%, 7.48 min

Example 37. 3-(4,4'-dichlorobenzhydryloxy)-N-[(S)- α -methylbenzyl]azetidine-1-carboxamide (46)

15 This material was prepared from 3-(4,4'-dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available isocyanate, using the procedure described for compound (5).

NMR (400MHz, d^6 -DMSO) δ_H 1.30 (3H, d, J 7.5 Hz), 3.63 (2H, m), 3.89 (2H, m), 4.30 (1H, m), 4.75 (1H, m), 5.55 (1H, s), 6.71 (1H, d, J 8.0 Hz), 7.18 (1H, m), 7.27 (4H, m), 7.39 (8H, m)

20 LC (50/80) 95.3%, 7.48 min

Example 38. 3-(4,4'-dichlorobenzhydryloxy)-N-(4-methoxybenzyl)azetidine-1-carboxamide (47)

25 This material was prepared from 3-(4,4'-dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available isocyanate, using the procedure described for compound (5).

NMR (400MHz, d^6 -DMSO) δ_H 3.61 (2H, m), 3.71 (3H, s), 3.88 (2H, m), 4.08 (2H, m), 4.30 (1H, m), 5.56 (1H, s), 6.84 (3H, m), 7.14 (2H, m), 7.35 – 7.44 (8H, m)

LC (50/80) 94.9%, 7.30 min

30

Example 39. 3-(4,4'-dichlorobenzhydryloxy)-N-[(R)- α -methylbenzyl]azetidine-1-carboxamide (48)

This material was prepared from 3-(4,4'-dichlorobenzhydryloxy)azetidine (36) and the

corresponding commercially available isocyanate, using the procedure described for compound (5).

NMR (400MHz, d^6 -DMSO) δ_H 1.31 (3H, d, J 7.0 Hz), 3.62 (2H, m), 3.89 (2H, m), 4.30 (1H, m), 4.73 (1H, m), 5.55 (1H, s), 6.66 (1H, d, J 8.0 Hz), 7.18 (1H, m), 7.28 (4H, m),

5 7.39 (8H, m)

LC (80/20) 96.8%, 1.25 min

Example 40. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(cyclopropylmethyl)azetidine-1-carboxamide (49)

10 This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available amine using the procedure described for compound (15) (11.0 mg, 10%).

NMR (400MHz, d^6 -DMSO) δ_H 0.10 (2H, m), 0.33 (2H, m), 0.85 (1H, m), 2.82 (2H, d, J 6.0 Hz), 3.59 (2H, m), 3.85 (2H, m), 4.29 (1H, m), 5.55 (1H, s), 6.38 (1H, t, J 6.0 Hz), 6.39

15 (7H, m)

LC (50/80) 99.5%, 6.83 min

Example 41. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(benzhydryl)azetidine-1-carboxamide (50)

20 This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available amine using the procedure described for compound (15).

NMR (400MHz, d^6 -DMSO) δ_H 3.67 (2H, m), 3.95 (2H, m), 4.31 (1H, m), 5.56 (1H, m), 5.95 (1H, d, J 9.0 Hz), 7.19 – 7.43 (20H, m)

25 LC (50/80) 96.5%, 8.61 min

Example 42. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(furanylmethyl)azetidine-1-carboxamide (51)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the
30 corresponding commercially available amine using the procedure described for compound (15).

MS 432 $[M + H]^+$

LC (50/80) 96.6%, 6.70 min

Example 43. 3-(4,4'-dichlorobenzhydryloxy)-N-(2-*exo*-norbornanyl)azetidine-1-carboxamide (52)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the
5 corresponding commercially available amine using the procedure described for compound (15).

MS 446 $[M + H]^+$

LC (50/80) 98.2%, 7.77 min

10 **Example 44. 3-(4,4'-dichlorobenzhydryloxy)-N-(cyclohexylmethyl)azetidine-1-carboxamide (53)**

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the
corresponding commercially available amine using the procedure described for compound
(15).

15 MS 448 $[M + H]^+$

LC (50/80) 96.2%, 8.02 min

Example 45. 3-(4,4'-dichlorobenzhydryloxy)-N-(thiophen-2-yl-methyl)azetidine-1-carboxamide (54)

20 This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the
corresponding commercially available amine using the procedure described for compound
(15).

MS 448 $[M + H]^+$

LC (50/80) 95.9%, 7.12 min

25

Example 46. 3-(4,4'-dichlorobenzhydryloxy)-N-(6-Fluoro-4*H*-benzo[1,3]dioxin-8-yl-methyl)azetidine-1-carboxamide (55)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the
corresponding commercially available amine using the procedure described for compound
30 (15).

MS 518 $[M + H]^+$

LC (50/80) 98.4%, 7.43 min

Example 47. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(2,3-dihydrobenzofuran-5-yl-methyl)azetidine-1-carboxamide (56)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available amine using the procedure described for compound (15).

MS 484 $[M + H]^+$

LC (50/80) 95.2%, 7.30 min

Example 48. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(furanylmethyl)azetidine-1-carboxamide (57)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available amine using the procedure described for compound (15).

MS 432 $[M + H]^+$

LC (50/80) 97.1%, 6.70 min

Example 49. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(benzo[1,3]dioxol-5-yl-methyl)azetidine-1-carboxamide (58)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available amine using the procedure described for compound (15).

MS 486 $[M + H]^+$

LC (50/80) 92.1%, 7.41 min

Example 50. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(2,3-dihydrobenzo[1,4]dioxin-2-yl-methyl)azetidine-1-carboxamide (59)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available amine using the procedure described for compound (15).

MS 500 $[M + H]^+$

LC (50/80) 95.8%, 7.82 min

Example 51. 3-(4,4'-dichlorobenzhydryloxy)-N-(2-thiophen-2-yl-thiazol-4-yl-methyl)azetidine-1-carboxamide (60)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available amine using the procedure described for compound

5 (15).

MS 531 $[M + H]^+$

LC (50/80) 92.8%, 7.68 min

Example 52. 3-(4,4'-dichlorobenzhydryloxy)-N-(benzo[b]thiophen-3-yl-methyl)azetidine-1-carboxamide (61)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available amine using the procedure described for compound (15).

MS 498 $[M + H]^+$

15 LC (50/80) 98.1%, 8.26 min

Example 53. 3-(4,4'-dichlorobenzhydryloxy)-N-(thiophen-3-yl-methyl)azetidine-1-carboxamide (62)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available amine using the procedure described for compound (15).

MS 448 $[M + H]^+$

LC (50/80) 97.9%, 7.22 min

Example 54. 3-(4,4'-dichlorobenzhydryloxy)-N-(5-methylisoxazol-3-yl-methyl)azetidine-1-carboxamide (63)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available amine using the procedure described for compound (15).

30 MS 447 $[M + H]^+$

LC (50/80) 89.7%, 6.38 min

Example 55. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(benzo[*b*]thiophen-2-yl-methyl)azetidine-1-carboxamide (64)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available amine using the procedure described for compound (15).

MS 498 [M + H]⁺

LC (50/80) 95.6%, 8.23 min

Example 56. 3-(4,4'-dichlorobenzhydryloxy)-*N*-(2-adamantyl)azetidine-1-carboxamide (65)

This material was prepared from 3-(4,4'-Dichlorobenzhydryloxy)azetidine (36) and the corresponding commercially available amine using the procedure described for compound (15).

NMR (400MHz, *d*⁶-DMSO) δ_{H} 1.43 (2H, m), 1.65 – 1.80 (8H, m), 1.94 (2H, m), 3.65 (2H, m), 3.92 (2H, m), 4.27 (1H, m), 5.77 (1H, d, *J* 6.5 Hz), 7.35 – 7.43 (6H, m)

LC (50/80) 97.0%, 8.99 min

Preparation of 2,2'-dichlorobenzhydrol (66)

This material was prepared from 2,2'-dichlorobenzophenone using the procedure described for compound (7) (8.96 g, 89%).

NMR (400MHz, *d*⁶-DMSO) δ_{H} 6.09 (1H, d, *J* 5.5 Hz), 6.62 (1H, d, *J* 5.0 Hz), 7.27 – 7.44 (8H, m)

LC (50/80) 99.0%, 4.08 min

25 Preparation of 1-benzhydryl-3-(2,2'-dichlorobenzhydryloxy)azetidine (67)

This material was prepared from 1-benzhydryl-3-azetidinol (1) (13.5 mmol) and 4,4'-dichlorobenzhydrol (27.0 mmol) using the procedure described for compound (3).

Preparation of 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68)

30 This material was prepared from compound (67) (12.7 mmol) using the procedure described for compound (9) (1.58 g, 48%).

NMR (400MHz, *d*⁶-DMSO) δ_{H} 3.84 – 3.94 (2H, br m), 4.05 – 4.15 (2H, br m), 4.49 (1H, q, *J* 6.0 Hz), 6.10 (1H, s), 7.32 – 7.44 (7H, m), 7.50 (2H, m), 9.12 (1H, br s)

Example 57. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(*tert*-butyl)azetidine-1-carboxamide (69)

A solution of 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) (0.29 mmol),
 5 *tert*-butyl isocyanate (0.29 mmol) and triethylamine (0.58 mmol) in dichloromethane (3 mL) was shaken at room temperature overnight, quenched with water, filtered through a PTFE phase separator cartridge and reduced *in vacuo* to yield a colourless gum (52 mg, 44%).

NMR (400MHz, d^6 -DMSO) δ_H 1.20 (9H, s), 3.65 (2H, m), 3.92 (2H, m), 4.31 (1H, m),
 10 5.43 (1H, s), 7.38 (6H, m), 7.48 (2H, m)
 LC (50/80) 98.8%, 6.53 min

Example 58. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(*iso*-propyl)azetidine-1-carboxamide (70)

15 This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) and the corresponding commercially available isocyanate using the procedure described for compound (69).

NMR (400MHz, d^6 -DMSO) δ_H 1.00 (2H, d, J 6.5 Hz), 3.65 (3H, m), 3.92 (2H, m), 4.34 (1H, m), 6.03 (2H, m), 7.38 (6H, m), 7.48 (2H, m)
 20 LC (50/80) 98.9%, 5.76 min

Example 59. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(*sec*-butyl)azetidine-1-carboxamide (71)

This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride
 25 (68) and the corresponding commercially available isocyanate using the procedure described for compound (69).

NMR (400MHz, d^6 -DMSO) δ_H 3.45 (1H, q, J 7.0 Hz), 3.65 (2H, m), 3.93 (2H, m), 4.35 (1H, m), 5.98 (2H, d, J 8.0 Hz), 6.06 (1H, s), 7.38 (6H, m), 7.47 (2H, m)
 LC (50/80) 97.9%, 6.24 min

30

Example 60. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(*n*-propyl)azetidine-1-carboxamide (72)

This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) and the corresponding commercially available isocyanate using the procedure described for compound (69).

NMR (400MHz, d^6 -DMSO) δ_H 0.79 (2H, t, J 7.5 Hz), 1.38 (2H, q, J 7.0 Hz), 2.90 (2H, m),
5 3.65 (2H, m), 3.93 (2H, m), 4.36 (1H, m), 6.06 (1H, s), 6.28 (1H, m), 7.38 (6H, m), 7.47
(2H, m)

LC (50/80) 99.4%, 5.82 min

Example 61. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(allyl)azetidine-1-carboxamide (73)

10 This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) and the corresponding commercially available isocyanate using the procedure described for compound (69).

NMR (400MHz, d^6 -DMSO) δ_H 3.58 (2H, m), 3.68 (2H, m), 3.96 (2H, m), 4.37 (1H, m),
15 5.02 (2H, m), 5.76 (1H, m), 6.07 (1H, m), 6.49 (1H, t, J 5.5 Hz), 7.38 (6H, m), 7.49 (2H,
m)

LC (50/80) 95.9%, 5.59 min

Example 62. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(*n*-butyl)azetidine-1-carboxamide (74)

20 This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) and the corresponding commercially available isocyanate using the procedure described for compound (69).

NMR (400MHz, d^6 -DMSO) δ_H 0.85 (3H, t, J 7.5 Hz), 1.23 (2H, m), 1.31 (2H, m), 2.93
(1H, q, J 7.0 Hz), 3.66 (2H, m), 3.92 (2H, m), 4.35 (1H, m), 6.05 (1H, s), 6.24 (1H, t, J 5.5
25 Hz), 7.38 (6H, m), 7.47 (2H, m)

LC (50/80) 98.6%, 6.53 min

Example 63. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(cyclopentyl)azetidine-1-carboxamide (75)

30 This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) and the corresponding commercially available isocyanate using the procedure described for compound (69).

NMR (400MHz, d^6 -DMSO) δ_H 1.31 (2H, m), 1.44 (2H, m), 1.61 (2H, m), 1.73 (2H, m), 3.65 (2H, m), 3.80 (1H, m), 3.93 (2H, m), 4.35 (1H, m), 6.06 (1H, s), 6.11 (1H, m), 7.38 (6H, m), 7.48 (2H, m)

LC (50/80) 99.7%, 6.60 min

5

Example 64. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(cyclohexyl)azetidine-1-carboxamide (76)

This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) and the corresponding commercially available isocyanate using the procedure described for compound (69).

10

NMR (400MHz, d^6 -DMSO) δ_H 1.12 (5H, m), 1.60 (5H, m), 3.64 (2H, m), 3.92 (2H, m), 4.32 (1H, m), 6.05 (2H, m), 7.37 (6H, m), 7.46 (2H, m)

LC (50/80) 98.7%, 7.06

15

Example 65. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(phenethyl)azetidine-1-carboxamide (77)

This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) and the corresponding commercially available isocyanate using the procedure described for compound (69).

20

NMR (400MHz, d^6 -DMSO) δ_H 2.70 (2H, t, J 7.5 Hz), 3.15 (2H, m), 3.65 (2H, m), 3.93 (2H, m), 4.36 (1H, m), 6.06 (1H, s), 6.40 (1H, t, J 5.5 Hz), 7.17 (3H, m), 7.26 (2H, m), 7.38 (6H, m), 7.48 (2H, m)

LC (50/80) 98.7%, 7.00 min

25

Example 66. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(1-adamantyl)azetidine-1-carboxamide (78)

This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) and the corresponding commercially available isocyanate using the procedure described for compound (69).

30

NMR (400MHz, d^6 -DMSO) δ_H 1.58 (7H, br m), 1.85 (7H, br m), 1.97 (3H, br m), 3.63 (2H, m), 3.91 (2H, m), 4.31 (1H, m), 5.51 (1H, s), 6.06 (1H, s), 7.38 (6H, m), 7.47 (2H, m)

LC (50/80) 97.6%, 8.27 min

Example 67. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(6-Fluoro-4*H*-benzo[1,3]dioxin-8-yl-methyl)azetidine-1-carboxamide (79)

This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) and the corresponding commercially available amine using the procedure described
5 for compound (15) (77.7 mg, 80%).

MS 518 [M + H]⁺

LC (50/80) 88.3%, 6.81 min

**Example 68. 3-(2,2'-dichlorobenzhydryloxy)-*N*-[2-(1-piperidyl)benzyl]azetidine-1-
10 carboxamide (80)**

This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) and the corresponding commercially available amine using the procedure described for compound (15).

MS 525 [M + H]⁺

15 LC (50/80) 92.0%, 8.26 min

Example 69. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(*exo*-2-norbornanyl)azetidine-1-carboxamide (81)

This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride
20 (68) and the corresponding commercially available amine using the procedure described for compound (15).

MS 446 [M + H]⁺

LC (50/80) 95.5%, 7.30 min

Example 70. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(cyclohexylmethyl)azetidine-1-carboxamide (82)

This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) and the corresponding commercially available amine using the procedure described for compound (15).

30 MS 448 [M + H]⁺

LC (50/80) 97.9%, 7.53 min

Example 71. 3-(2,2'-dichlorobenzhydryloxy)-*N*-(benzo[*b*]thiophen-3-yl-methyl)-azetidine-1-carboxamide (83)

This material was prepared from 3-(2,2'-dichlorobenzhydryloxy)azetidine hydrochloride (68) and the corresponding commercially available amine using the procedure described for compound (15).

MS 498 [M + H]⁺

LC (50/80) 93.2%, 7.74 min

Preparation of 4,4'-dibromobenzhydrol (84)

This material was prepared from 4,4'-dibromobenzophenone using the procedure described for compound (7) (9.67 g, 96%).

NMR (400MHz, *d*⁶-DMSO) δ_H 5.68 (1H, d, *J* 4.0 Hz), 6.06 (1H, d, *J* 4.0 Hz), 7.31 (4H, m), 7.48 (4H, m)

LC (50/80) 99.7%, 6.29 min

Preparation of 1-benzhydryl-3-(4,4'-dibromobenzhydryloxy)azetidine (85)

This material was prepared from 4,4'-dibromobenzhydrol (84) using the procedure described for compound (8) (6.15 g, 66%).

NMR (400MHz, *d*⁶-DMSO) δ_H 2.80 (2H, m), 3.25 (2H, m), 4.14 (1H, t, *J* 6.0 Hz), 4.41 (1H, s), 5.47 (1H, s), 7.16 (2H, m), 7.25 (8H, m), 7.38 (4H, m), 7.52 (4H, m)

LC (50/80) 97.7%, 4.01 min

Preparation of 3-(4,4'-dibromobenzhydryloxy)azetidine hydrochloride (86)

This material was prepared from 1-benzhydryl-3-(4,4'-dibromobenzhydryloxy)azetidine (85) using the procedure described for compound (9) (1.15 mg, 30%).

NMR (400MHz, *d*⁶-DMSO) δ_H 3.85 (2H, br s), 4.02 (2H, br s), 4.38 (1H, q, *J* 5.5 Hz), 5.61 (1H, s), 7.31 (4H, m), 7.56 (4H, m), 8.71 (2H, br d)

Example 72. 3-(4,4'-dibromobenzhydryloxy)-*N*-(*tert*-butyl)azetidine-1-carboxamide (87)

This material was prepared from 3-(4,4'-dibromobenzhydryloxy)azetidine hydrochloride (86) using the procedure described for compound (10) (92.0 mg, 80%).

NMR (400MHz, d^6 -DMSO) δ_H 1.20 (9H, s), 3.58 (2H, m), 3.85 (2H, m), 4.21 (1H, m), 5.51 (1H, s), 5.61 (1H, s), 7.30 (4H, m), 7.54 (4H, m)
LC (50/80) 93.6%, 7.41 min

5 **Example 73. 3-(4,4'-dibromobenzhydryloxy)-*N*-(*iso*-propyl)azetidine-1-carboxamide (88)**

This material was prepared from 3-(4,4'-dibromobenzhydryloxy)azetidine hydrochloride (86) using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 1.00 (6H, d, J 6.5 Hz), 3.56 (2H, m), 3.64 (1H, m), 3.84 (2H, m), 4.27 (1H, m), 5.51 (1H, s), 6.00 (1H, m), 7.30 (4H, m), 7.55 (4H, m)
10 LC (50/80) 97.5%, 7.15 min

Example 74. 3-(4,4'-dibromobenzhydryloxy)-*N*-(*iso*-butyl)azetidine-1-carboxamide (89)

15 This material was prepared from 3-(4,4'-dibromobenzhydryloxy)azetidine hydrochloride (86) using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 0.78 (3H, t, J 7.5 Hz), 0.97 (3H, d, J 6.5 Hz), 1.33 (2H, m), 3.45 (1H, m), 3.58 (2H, m), 3.84 (2H, m), 4.28 (1H, m), 5.51 (1H, s), 5.96 (1H, d, J 8.5 Hz), 7.30 (4H, m), 7.54 (4H, m)
20 LC (50/80) 98.6%, 7.41 min

Example 75. 3-(4,4'-dibromobenzhydryloxy)-*N*-(*n*-propyl)azetidine-1-carboxamide (90)

This material was prepared from 3-(4,4'-dibromobenzhydryloxy)azetidine hydrochloride (86) using the procedure described for compound (10).

25 NMR (400MHz, d^6 -DMSO) δ_H 0.79 (3H, t, J 7.0 Hz), 1.35 (2H, m), 2.89 (2H, m), 3.58 (2H, m), 3.84 (2H, m), 4.28 (1H, m), 5.51 (1H, s), 6.25 (1H, t, J 6.0 Hz) 7.30 (4H, m), 7.54 (4H, m)
LC (50/80) 97.0%, 7.12 min

30

Example 76. 3-(4,4'-dibromobenzhydryloxy)-*N*-(*n*-butyl)azetidine-1-carboxamide (91)

This material was prepared from 3-(4,4'-dibromobenzhydryloxy)azetidine hydrochloride (86) using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 0.84 (3H, t, J 7.0 Hz), 1.23 (2H, m), 1.32 (2H, m), 2.93 (2H, m), 3.58 (2H, m), 3.84 (2H, m), 4.28 (1H, m), 5.51 (1H, s), 6.22 (1H, t, J 6.0 Hz),

5 7.30 (4H, m), 7.55 (4H, m)

LC (50/80) 98.0%, 7.42 min

Example 77. 3-(4,4'-dibromobenzhydryloxy)-*N*-(cyclopentyl)azetidine-1-carboxamide (92)

10 This material was prepared from 3-(4,4'-dibromobenzhydryloxy)azetidine hydrochloride (86) using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 1.32 (2H, m), 1.44 (2H, m), 1.59(2H, m), 1.73(2H, m), 3.60 (2H, m), 3.83 (3H, m), 4.27 (1H, m), 5.50 (1H, s), 6.09 (1H, m), 7.30 (4H, m), 7.55 (4H, m)

15 LC (50/80) 97.6%, 7.69 min

Example 78. 3-(4,4'-dibromobenzhydryloxy)-*N*-(cyclohexyl)azetidine-1-carboxamide (93)

This material was prepared from 3-(4,4'-dibromobenzhydryloxy)azetidine hydrochloride (86) using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 1.12 (5H, m), 1.55 (1H, br m), 1.67 (4H, br m), 3.56 (2H, m), 3.84 (2H, m), 4.28 (1H, m), 5.51 (1H, s), 6.00 (1H, m), 7.30 (4H, m), 7.54 (4H, m)

LC (50/80) 99.8%, 7.93 min

Example 79. 3-(4,4'-dibromobenzhydryloxy)-*N*-(phenethyl)azetidine-1-carboxamide (94)

This material was prepared from 3-(4,4'-dibromobenzhydryloxy)azetidine hydrochloride (86) using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 2.66 (2H, m), 3.15 (2H, m), 3.58 (2H, m), 3.84 (2H, m), 4.29 (1H, m), 5.51 (1H, s), 6.37 (1H, m), 7.18 (3H, m), 7.29 (6H, m), 7.55 (4H, m)

30 LC (50/80) 98.9%, 7.91 min

Example 80. 3-(4,4'-dibromobenzhydryloxy)-N-(1-adamantyl)azetidine-1-carboxamide (95)

This material was prepared from 3-(4,4'-dibromobenzhydryloxy)azetidine hydrochloride (86) using the procedure described for compound (10).

- 5 NMR (400MHz, d^6 -DMSO) δ_H 0.95 (1H, m), 1.58 (6H, m), 1.85 (6H, m), 1.97 (3H, m), 3.57 (2H, m), 3.81 (2H, m), 4.23 (1H, m), 5.50 (2H, m), 7.31 (4H, m), 7.55 (4H, m)
LC (50/80) 98.0%, 9.44 min

Preparation of 2-(trifluoromethyl)-4-chlorobenzhydrol (96)

- 10 Magnesium turnings (4.21 g, 170 mmol) were stirred under nitrogen for 10 min. Stirring was halted and a solution of 2-bromobenzotrifluoride (36.37 g, 160 mmol) in dry THF (160 mL) was added *via* a dropping funnel until the magnesium turnings were just covered. The reaction mixture was heated with a hot-air gun until localised turbidity was observed. At this point, stirring was initiated, and the rate of the reaction was subsequently controlled
15 with intermittent use of an ice-water bath, and varying the rate of addition of the remaining 2-bromobenzotrifluoride solution. After complete addition, the mixture was allowed to stir for 1 h, then used as a ~ 0.9 M solution.

- To a stirred solution of 4-chlorobenzaldehyde (2.17 g, 15 mmol) in anhydrous THF (10 mL) was added a solution of 2-(trifluoromethyl)phenylmagnesium bromide (~ 0.9 M; 18
20 mL, 16 mmol) over 2 min. After 16 h, the resultant mixture was partitioned between diethyl ether and 1N HCl. The aqueous phase was extracted with diethyl ether (2 x 30 mL) and the combined organic extracts were washed with 1N HCl, brine and dried ($MgSO_4$). Evaporation under reduced pressure afforded the desired product as an amber oil (4.63 g, 100%).

- 25 MS 269 $[M - OH]^+$
LC (50/80) 97.6%, 5.47 min

Preparation of 1-benzhydryl-3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine (97)

- 30 This material was prepared from 1-benzhydryl-3-azetidinol (1) (40.1 mmol) and 2-(trifluoromethyl)-4-chlorobenzhydrol (96) (80.2 mmol) using the procedure described for compound (3) (13.5 g, 66%).

NMR (400MHz, d^6 -DMSO) δ_H 2.74 (1H, br t), 2.86 (1H, br t), 3.20 (1H, br t), 3.29(1H, br t), 4.15 (1H, q, J 6.0 Hz), 4.39 (1H, s), 5.71 (1H, s), 7.16 (2H, m), 7.26 (6H, m), 7.38 (6H, m), 7.54 (1H, m), 7.70 (3H, m)

5 **Preparation of 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98)**

This material was prepared from 1-benzhydryl-3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine (97) (25.6 mmol) using the procedure described for compound (9) (8.2 g, 85%).

10 NMR (400MHz, d^6 -DMSO) δ_H 3.78 (1H, m), 3.97 (3H, m), 4.89 (1H, q, J 6.0 Hz), 5.85 (1H, s), 7.33 (2H, m), 7.44 (2H, m), 7.59 (1H, m), 7.76 (3H, m), 8.97 (1H, bs)

Example 81. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide (99)

15 This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) (1.32 mmol) and *tert*-butyl isocyanate (1.32 mmol) using the procedure described for compound (10) (474 mg, 81%).

NMR (400MHz, d^6 -DMSO) δ_H 1.20 (9H, s), 3.51 (1H, m), 3.65 (1H, m), 3.84 (2H, m), 4.25 (1H, m), 5.62 (1H, s), 5.73 (1H, s), 7.31 (2H, m), 7.39 (2H, m), 7.57 (1H, m), 7.75 (3H, m)

LC (50/80) 98.6%, 6.93 min

Example 82. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(*n*-propyl)azetidine-1-carboxamide (100)

25 This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 0.79 (3H, t, J 7.5 Hz), 1.33 (2H, m), 3.52 (1H, m), 3.65 (1H, m), 3.85 (2H, m), 4.30 (1H, m), 5.74 (1H, s), 6.23 (1H, s), 7.30 (2H, m), 7.42 (2H, m), 7.57 (1H, m), 7.75 (3H, m)

30 LC (50/80) 96.7% 6.46 min

Example 83. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(*iso*-propyl)azetidine-1-carboxamide (101)

This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 1.00 (6H, d, J 6.5 Hz), 3.54 (1H, m), 3.64 (2H, m), 3.84 (2H, m), 4.28 (1H, m), 5.74 (1H, s), 6.02 (1H, s), 7.30 (2H, m), 7.41 (2H, m), 7.58 (1H, m), 7.79 (3H, m)

LC (50/80) 98.2%, 6.22 min

10

Example 84. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(*n*-butyl)azetidine-1-carboxamide (102)

This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 0.84 (3H, t, J 7.5 Hz), 1.23 (2H, m), 1.32 (2H, m), 3.35 (1H, m), 3.65 (1H, m), 3.85 (2H, m), 4.29 (1H, m), 5.74 (1H, s), 6.23 (1H, s), 7.13 (2H, m), 7.42 (2H, m), 7.56 (1H, m), 7.74 (3H, m)

LC (50/80) 98.0%, 7.02 min

20

Example 85. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(*sec*-butyl)azetidine-1-carboxamide (103)

This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 0.78 (3H, m), 0.97 (3H, d, J 6.0 Hz), 1.33 (2H, m), 3.53 (1H, m), 3.65 (1H, m), 3.85 (2H, m), 4.28 (1H, m), 5.74 (1H, s), 5.97 (1H, br d), 7.31 (2H, m), 7.42 (2H, m), 7.57 (1H, m), 7.75 (3H, m)

LC (50/80) 98.0%, 6.87 min

30

Example 86. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(ethyl propionate-3-yl)azetidine-1-carboxamide (104)

This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 1.14 (3H, t, J 7.0 Hz), 2.38 (2H, t, J 7.0 Hz), 3.54 (1H, m),
 5 3.66 (1H, m), 3.85 (2H, m), 4.04 (2H, q, J 7.0 Hz), 4.30 (1H, m), 5.74 (1H, s), 6.37 (1H, br
 s), 7.31 (2H, m), 4.24 (2H, m), 5.57 (1H, m), 7.75 (3H, m)
 LC (50/80) 95.0%, 6.40 min

**Example 87. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(methyl 3-phenyl-
 10 propionate-2-yl)azetidine-1-carboxamide (105)**

This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 2.88 (1H, m), 2.97 (1H, m), 3.50 (1H, m), 3.62 (1H, m),
 15 3.84 (2H, m), 4.26 (2H, m), 5.73 (1H, s), 6.75 (1H, m), 7.23 (7H, m), 7.44 (2H, m), 7.56
 (1H, m), 7.75 (3H, m)
 LC (50/80) 96.0%, 7.40 min

**Example 88. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(ethyl)azetidine-1-
 20 carboxamide (106)**

This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 0.951 (3H, t, J 7.0 Hz), 2.96 (2H, m), 3.53 (1H, m), 3.64
 25 (1H, m), 3.86 (2H, m), 4.28 (1H, m), 5.74 (1H, s), 6.25 (1H, m), 7.30 (2H, m), 7.42 (2H,
 m), 7.56 (1H, m), 7.74 (3H, m)
 LC (80/20) 90.6%, 0.77 min

**Example 89. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-[(*S*)- α -methyl-
 30 benzyl]azetidine-1-carboxamide (107)**

This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 3.58 (1H, m), 3.70 (1H, m), 3.89 (2H, m), 4.32 (1H, m), 4.73 (1H, m), 6.67 (1H, m), 7.31 (6H, m), 7.42 (2H, m), 7.55 (1H, m), 7.79 (3H, m)
 LC (80/20) 96.0%, 1.09 min

5 Example 90. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(2,2,4-trimethylpent-4-yl)azetidine-1-carboxamide (108)

This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) and the corresponding isocyanate using the procedure described for compound (10).

10 NMR (400MHz, d^6 -DMSO) δ_H 0.92 (9H, s), 1.24 (6H, s), 1.64 (2H, s), 3.52 (1H, m), 3.65 (1H, m), 3.83 (2H, m), 4.25 (1H, m), 5.73 (1H, s), 7.30 (2H, m), 7.42 (2H, m), 7.57 (1H, m), 7.74 (3H, m)
 LC (80/20) 97.2%, 1.75 min

15 Example 91. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N(cyclopentyl)-azetidine-1-carboxamide (109)

This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) and the corresponding isocyanate using the procedure described for compound (10).

20 NMR (400MHz, d^6 -DMSO) δ_H 1.31 (2H, m), 1.44 (2H, m), 1.58 (2H, m), 1.73 (2H, m), 3.54 (1H, m), 3.67 (1H, m), 3.83 (3H, m), 4.28 (1H, m), 5.73 (1H, s), 6.07 (1H, m), 7.30 (2H, m), 7.42 (2H, m), 7.57 (1H, m), 7.74 (3H, m)
 LC (80/20) 99.5%, 1.03 min

25 Example 92. 3-(2,4'-dichlorobenzhydryloxy)-N-(2,2,4-trimethylpent-4-yl)azetidine-1-carboxamide (110)

This material was prepared from 3-(2,4'-dichlorobenzhydryloxy)azetidine hydrochloride (9) and the corresponding isocyanate using the procedure described for compound (10).

MS 464 [M + H]⁺

30 LC (80/20) 97.9%, 1.80min

Example 93. 3-(2,4'-dichlorobenzhydryloxy)-N-(2-methylbut-2-yl)azetidine-1-carboxamide (111)

This material was prepared from 3-(2,4'-dichlorobenzhydryloxy)azetidine hydrochloride (9) and the corresponding isocyanate using the procedure described for compound (10).

MS 422 [M + H]⁺

LC (50/80) 99.6%, 1.15min

5

Preparation of 2-(trifluoromethyl)-2'-fluoro-4'-bromobenzhydrol (112)

This material was prepared from 2-(trifluoromethyl)phenylmagnesium bromide (60 mmol) and 4-bromo-2-fluorobenzaldehyde (54 mmol) using the procedure described for compound (96) (12.3 g, 74%).

10 NMR (400MHz, *d*⁶-DMSO) δ_{H} 5.99 (1H, br d), 6.33 (1H, d, *J* 4.5 Hz), 7.27 (2H, m), 7.38 (2H, m), 7.57 (2H, m), 7.71 (1H, m)

Preparation of 1-benzhydryl-3-[2-(trifluoromethyl)-2'-fluoro-4'-bromobenzhydryloxy]azetidine (113)

15 This material was prepared from 1-benzhydryl-3-azetidinol (1) (23.0 mmol) and 2-(trifluoromethyl)-2'-fluoro-4'-bromobenzhydrol (112) (34.0 mmol) using the procedure described for compound (3) (8.84 g, 67%).

NMR (400MHz, *d*⁶-DMSO) δ_{H} 2.76 (1H, t, *J* 6.5Hz), 2.87 (1H, t, *J* 6.5Hz), 3.23 (1H, br t), 3.29 (1H, br t), 4.15 (1H, q), 4.39 (1H, s), 5.70 (1H, s), 7.17 (2H, m), 7.25 (6H, m), 7.37
20 (6H, m), 7.59 (2H, m), 7.73 (1H, m)

Preparation of 3-[2-(trifluoromethyl)-2'-fluoro-4'-bromobenzhydryloxy]azetidine hydrochloride (114)

This material was prepared from 1-benzhydryl-3-[2-(trifluoromethyl)-2'-fluoro-4'-
25 bromobenzhydryloxy]azetidine (113) (15 mmol) using the procedure described for compound (9) (2.26 g, 51%).

NMR (400MHz, *d*⁶-DMSO) δ_{H} 3.78 (1H, br s), 3.96 (3H, br d), 4.42 (1H, m), 5.83 (1H, s), 7.33 (2H, m), 7.41 (2H, m), 7.70 (3H, m)

LC (50/80) 99.7%, 4.67 min

30

Example 94. 3-[2-(trifluoromethyl)-2'-fluoro-4'-bromobenzhydryloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide (115)

This material was prepared from 3-[2-(trifluoromethyl)-2'-fluoro-4'-bromobenzhydryloxy]azetidine hydrochloride (114) and *tert*-butyl isocyanate (4.54 mmol) using the procedure described for compound (5) (1.33 g, 58%).

NMR (400MHz, d^6 -DMSO) δ_H 1.20 (9H, s), 3.58 (1H, m), 3.64 (1H, m), 3.88 (2H, m),
5 4.26 (1H, m), 5.98 (1H, s), 7.18 (1H, m), 7.44 (1H, m), 7.61 (2H, m), 7.78 (3H, m)

LC (50/80) 99.0%, 7.15 min

Found: C, 52.29; H, 4.61; N, 5.63, C₂₂H₂₃BrF₄N₂O₂ requires: C, 52.50; H, 4.61; N, 5.56%

10 Preparation of 2-(trifluoromethyl)-4'-(methylthio)benzhydrol (116)

This material was prepared from 2-(trifluoromethyl)phenylmagnesium bromide (32 mmol) and 4-(methylthio)benzaldehyde (30 mmol) using the procedure described for compound (96) (9.4 g, 100%).

NMR (400MHz, CDCl₃) δ_H 6.26 (1H, s), 7.21 (2H, m), 7.28 (2H, m), 7.39 (1H, m), 7.55
15 (1H, m), 7.64 (2H, m)

Preparation of 1-benzhydryl-3-[2-(trifluoromethyl)-4'-(methylthio)-benzhydryloxy]azetidine (117)

This material was prepared from 1-benzhydryl-3-azetidinol (1) (15 mmol) and 2-
20 (trifluoromethyl)-4'-(methylthio)benzhydrol (116) (30 mmol) using the procedure described for compound (3) (4.68 g, 60%).

NMR (400MHz, d^6 -DMSO) δ_H 2.42 (3H, s), 2.75 (1H, m), 2.85 (1H, m), 3.21 (1H, m),
3.29 (1H, m), 4.14 (1H, m), 4.38 (1H, s), 5.66 (1H, s), 7.21 (10H, m), 7.37 (4H, m), 7.51
(1H, m), 7.70 (3H, m)

25

Preparation of 3-[2-trifluoromethyl-4'-(methylthio)benzhydryloxy]azetidine hydrochloride (118)

This material was prepared from 1-benzhydryl-3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]azetidine (117) (8.7 mmol) using the procedure described for
30 compound (9) (2.29 g, 68%).

NMR (400MHz, d^6 -DMSO) δ_H 3.89 (4H, br m), 4.41 (1H, m), 5.80 (1H, s), 7.24 (4H, s),
7.57 (1H, m), 7.75 (3H, m), 9.30 (2H, br s)

LC (50/80) 94.5%, 3.55 min

Example 95. 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-*N*-(*tert*-butyl)-azetidine-1-carboxamide (119)

This material was prepared from 3-[2-trifluoromethyl-4'-(methylthio)benzhydryloxy]azetidine hydrochloride (118) (1.28 mmol), *tert*-butyl isocyanate (1.28 mmol) and mp-carbonate (2.62mmol/g, 3.85 mmol) using the procedure described for compound (10) (433 mg, 75%).

NMR (400MHz, d^6 -DMSO) δ_H 1.20 (9H, s), 2.44 (3H, s), 3.53 (1H, m), 3.64 (1H, m), 3.83 (2H, m), 4.22(1H, m), 5.68(1H, s), 7.22 (4H, m), 7.54 (1H, m), 7.74 (3H, m)

10 LC (50/80) 98.0%, 7.00 min

Example 96. 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-*N*-(*iso*-propyl)azetidine-1-carboxamide (120)

This material was prepared from 3-[2-trifluoromethyl-4'-(methylthio)benzhydryloxy]azetidine hydrochloride (118) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 1.00 (6H, d, J 6.5 Hz), 2.44 (3H, s), 3.54 (1H, m), 3.64 (2H, m), 3.84 (2H, m), 4.27 (1H, m), 5.69 (1H, s), 6.02 (1H, m), 7.22 (4H, m), 7.55 (1H, m), 7.74 (3H, m)

20 LC (50/80) 99.0%, 6.36 min

Example 97. 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-*N*-(*sec*-butyl)-azetidine-1-carboxamide (121)

This material was prepared from 3-[2-trifluoromethyl-4'-(methylthio)benzhydryloxy]azetidine hydrochloride (118) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 0.78 (3H, t, J 7.0 Hz), 0.97 (3H, d, J 7.5 Hz), 1.32 (2H, m), 2.45 (3H, s), 3.45 (1H, m), 3.54 (1H, m), 3.65 (1H, m), 3.85 (2H, m), 4.27(1H, m), 5.70 (1H, s), 5.96 (1H, s), 7.22 (4H, m), 7.55 (1H, m), 7.74 (3H, m)

30 LC (50/80) 98.0%, 6.84 min

Example 98. 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-*N*-(benzyl)-azetidine-1-carboxamide (122)

This material was prepared from 3-[2-trifluoromethyl-4'-(methylthio)benzhydryloxy]azetidine hydrochloride (118) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 2.44 (3H, s), 3.60 (1H, m), 3.69 (1H, m), 3.90 (2H, m),
 5 4.15 (2H, m), 4.31(1H, m), 5.70 (1H, s), 6.87 (1H, m), 7.24 (8H, m), 7.55 (1H, m), 7.75 (3H, m)

LC (50/80) 96.1%, 7.17min

Preparation of 2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydrol (123)

10 This material was prepared from 4-chlorophenylmagnesium bromide (28.6 mmol) and 4-fluoro-2-(trifluoromethyl)benzaldehyde (26.0 mmol) using the procedure described for compound (2) (6.04 g, 76%).

NMR (400MHz, d^6 -DMSO) δ_H 6.00 (1H, br d), 6.33 (1H, d, J 4.5 Hz), 7.26 (2H, m), 7.38 (2H, m), 7.57 (2H, m), 7.12 (1H, m)

15

Preparation of 1-benzhydryl-3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]azetidine (124)

This material was prepared from 1-benzhydryl-3-azetidinol (1) (9.8 mmol) and 2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydrol (123) (19.7 mmol) using the procedure
 20 described for compound (3) (2.31 g, 45%).

NMR (400MHz, d^6 -DMSO) δ_H 2.76 (1H, t, J 6.5 Hz), 2.86 (1H, t, J 6.5 Hz), 3.23 (1H, t, J 6.5 Hz), 3.30 (1H, t, J 6.5 Hz), 4.16 (1H, m), 4.40 (1H, s), 5.70 (1H, s), 7.17 (2H, m), 7.26 (6H, m), 7.37 (6H, m), 7.60 (2H, m), 7.75(1H, m)

25 Preparation of 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]azetidine hydrochloride (125)

This material was prepared from 1-benzhydryl-3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]azetidine (124) (3.8 mmol) using the procedure described for compound (9) (1.45 g, 97%).

30 NMR (400MHz, d^6 -DMSO) δ_H 3.31 (1H, br s), 3.78 (1H, br s), 3.96 (3H, br d), 4.40 (1H, m), 5.83 (1H, s), 7.32 (2H, m), 7.45 (2H, m), 7.70 (3H, m), 8.97 (2H, br d)

LC (50/80) 99.7%, 4.67min

Example 99. 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide (126)

This material was prepared from 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]azetidine hydrochloride (125) (0.25 mmol), *tert*-butyl isocyanate (0.25 mmol) and MP-carbonate (2.62 mmol/g, 0.76 mmol) using the procedure described for compound (10) (72.4 mg, 63%).

NMR (400MHz, d^6 -DMSO) δ_H 1.21 (9H, s), 3.52 (1H, m), 3.64 (1H, m), 3.84 (2H, m), 4.25 (1H, m), 5.71 (1H, s), 7.30 (2H, m), 7.42 (2H, m), 7.62 (2H, m), 7.77(1H, m)

LC (50/80) 95.0%, 7.35 min

10

Example 100. 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-*N*-(*iso*-propyl)azetidine-1-carboxamide (127)

This material was prepared 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]azetidine hydrochloride (125) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 1.00 (6H, d, J 6.5 Hz), 3.51 (1H, m), 3.65 (2H, m), 3.83(2H, m), 4.28 (1H, m), 5.72 (1H, s), 6.02 (1H, m), 7.32 (2H, m), 7.40 (2H, m), 7.64 (2H, m), 7.79 (1H, m)

LC (50/80) 99.0%, 6.84 min

20

Example 101. 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-*N*-(*sec*-butyl)azetidine-1-carboxamide (128)

This material was prepared 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]azetidine hydrochloride (125) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 0.78 (3H, t, J 7.5 Hz), 0.97 (3H, d, J 6.5 Hz), 1.33 (2H, m), 3.45 (1H, m), 3.53 (1H, m), 3.65 (1H, m), 3.85 (2H, m), 4.30 (1H, m), 5.73 (1H, s), 5.96 (1H, m), 7.30 (2H, m), 7.43 (2H, m), 7.62 (2H, m), 7.78 (1H, m)

LC (50/80) 99.0%, 7.29 min

30

Example 102. 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-*N*-(cyclohexyl)azetidine-1-carboxamide (129)

This material was prepared 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]azetidine hydrochloride (125) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 1.12 (5H, m), 1.53 (1H, m), 1.66 (4H, m), 3.52 (1H, m),
 5 3.64 (1H, m), 3.83 (2H, m), 4.28 (1H, m), 5.71 (1H, s), 6.01 (1H, m), 7.31 (2H, m), 7.41 (2H, m), 7.62 (2H, m), 7.70 (1H, m)
 LC (50/80) 99.9%, 7.77 min

Example 103. 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(benzyl)azetidine-1-carboxamide (130)

This material was prepared 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]azetidine hydrochloride (125) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 3.58 (1H, m), 3.70 (1H, m), 3.91 (2H, m), 4.16 (2H, m),
 15 4.32 (1H, m), 5.74 (1H, s), 6.87 (1H, m), 6.12 (3H, m), 7.30 (4H, m), 7.43 (2H, m), 7.62 (2H, m), 7.85 (1H, m)
 LC (50/80) 94.0%, 7.49 min

Preparation of 2-(trifluoromethyl)benzhydrol (131)

20 This material was prepared from 2-(trifluoromethyl)phenylmagnesium bromide (16 mmol) and benzaldehyde (15 mmol) using the procedure described for compound (96) (3.7 g, 98%).

NMR (400MHz, $CDCl_3$) δ_H 6.31 (1H, s), 7.26 (1H, m), 7.36 (5H, m), 7.53 (1H, m), 7.65 (2H, m)

25

Preparation of 1-benzhydryl-3-[2-(trifluoromethyl)benzhydryloxy]azetidine (132)

This material was prepared from 1-benzhydrol-3-azetidinol (1) (7.5 mmol) and 2-(trifluoromethyl)benzhydrol (131) (15 mmol) using the procedure described for compound (3) (1.81 g, 51%).

30 NMR (400MHz, d^6 -DMSO) δ_H 2.75 (1H, br t), 2.85 (1H, br t), 3.21 (1H, br t), 3.27 (1H, br t), 4.15 (1H, m), 4.38 (1H, s), 5.71 (1H, s), 7.12 – 7.40 (12H, m), 7.49 – 7.72 (7H, m),

Preparation 3-[2-(trifluoromethyl)benzhydryloxy]azetidine hydrochloride (133)

This material was prepared from 1-benzhydryl-3-[2-(trifluoromethyl)-benzhydryloxy]azetidine (132) (3.8 mmol) using the procedure described for compound (9) (0.70 g, 60%).

NMR (400MHz, d^6 -DMSO) δ_H 3.89 (4H, br m), 4.41 (1H, m), 5.80 (1H, s), 7.29 (3H, m),
 5 7.35 (2H, m), 7.55 (1H, m), 7.74 (3H, m), 9.30 (2H, br s)
 LC (50/80) 96.6%, 1.60 min

Example 104. 3-[2-(trifluoromethyl)benzhydryloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide (134)

10 This material was prepared from 3-[2-(trifluoromethyl)benzhydryloxy]azetidine hydrochloride (133) (0.33 mmol), *tert*-butyl isocyanate (0.33 mmol) and MP-carbonate (2.62 mmol/g, 0.98 mmol) using the procedure described for compound (10) (99.5 mg, 75%).

NMR (400MHz, d^6 -DMSO) δ_H 1.20 (9H, s), 3.54 (1H, m), 3.66 (1H, m), 3.84 (2H, m),
 15 4.23 (1H, m), 5.63 (1H, s), 7.29 (3H, m), 7.35 (2H, m), 7.55 (1H, m), 7.74 (3H, m)
 LC (50/80) 93.0%, 6.24 min

Example 105. 3-[2-(trifluoromethyl)benzhydryloxy]-*N*-(*iso*-propyl)azetidine-1-carboxamide (135)

20 This material was prepared 3-[2-(trifluoromethyl)benzhydryloxy]azetidine hydrochloride (133) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 1.00 (6H, d, J 6.5 Hz), 3.55 (1H, m), 3.65 (2H, m), 3.84 (2H, m), 4.28 (1H, m), 5.74 (1H, s), 7.32 (5H, m), 7.55 (1H, m), 7.74 (3H, m)
 LC (50/80) 91.0%, 5.51 min

25

Example 106. 3-[2-(trifluoromethyl)benzhydryloxy]-*N*-(*sec*-butyl)azetidine-1-carboxamide (136)

This material was prepared 3-[2-(trifluoromethyl)benzhydryloxy]azetidine hydrochloride (133) and the corresponding isocyanate using the procedure described for compound (10).

30 NMR (400MHz, d^6 -DMSO) δ_H 0.782 (3H, m), 0.972 (3H, d, J 6.0 Hz), 1.33 (2H, m), 3.45 (1H, m), 3.54 (1H, m), 3.65 (1H, m), 3.85 (2H, m), 4.28 (1H, m), 5.74 (1H, s), 7.32 (5H, m), 7.55 (1H, m), 7.74 (3H, m)
 LC (50/80) 94.0%, 6.04 min

Example 107. 3-[2-(trifluoromethyl)benzhydryloxy]-*N*-(cyclohexyl)azetidine-1-carboxamide (137)

This material was prepared 3-[2-(trifluoromethyl)benzhydryloxy]azetidine hydrochloride (133) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 1.12 (5H, m), 1.55 (1H, m), 1.67 (4H, m), 3.54 (1H, m), 3.65 (1H, m), 3.85 (2H, m), 4.22 (1H, m), 5.74 (1H, s), 7.32 (5H, m), 7.55 (1H, m), 7.74 (3H, m)

LC (50/80) 96.0%, 6.79 min

Example 108. 3-[2-(trifluoromethyl)benzhydryloxy]-*N*-(benzyl)azetidine-1-carboxamide (138)

This material was prepared 3-[2-(trifluoromethyl)benzhydryloxy]azetidine hydrochloride (133) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 3.59 (1H, m), 3.71 (1H, m), 3.91 (2H, m), 4.15 (2H, m), 4.31 (1H, m), 5.75 (1H, s), 6.87 (1H, m), 7.21 (3H, m), 7.32 (6H, m), 7.55 (1H, m), 7.75 (3H, m)

LC (50/80) 95.5%, 6.45 min

20 Preparation of 2-(trifluoromethyl)-4'-(trifluoromethoxy)benzaldehyde (139)

This material was prepared from 2-(trifluoromethyl)phenylmagnesium bromide (16 mmol) and 4-(trifluoromethoxy)benzaldehyde (15 mmol) using the procedure described for compound (96) (5.24 g, 100%).

NMR (400MHz, $CDCl_3$) δ_H 6.31 (1H, s), 7.17 (2H, m), 7.39 (3H, m), 7.57 (2H, m), 7.68 (1H, m)

Preparation of 1-benzhydryl-3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)-benzhydryloxy]azetidine (140)

This material was prepared from 1-benzhydryl-3-azetidinol (1) (7.5 mmol) and 2-(trifluoromethyl)-4'-(trifluoromethoxy)benzaldehyde (139) (15 mmol) using the procedure described for compound (3) (2.65 g, 63%).

NMR (400MHz, d^6 -DMSO) δ_H 2.75 (1H, m), 2.85 (1H, m), 3.21 (1H, m), 3.30 (1H, m), 4.15 (1H, m), 4.39 (1H, s), 5.76 (1H, s), 7.16 (2H, m), 7.25 (3H, m), 7.37 (8H, m), 7.52 (1H, m), 7.72 (3H, m)

Preparation 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]azetidine hydrochloride (141)

This material was prepared from 1-benzhydryl-3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzyhydroxy]azetidine (140) (4.8 mmol) using the procedure described for compound (9) (1.32 g, 65%).

NMR (400MHz, d^6 -DMSO) δ_H 3.89 (4H, br m), 4.41 (1H, m), 5.80 (1H, s), 7.24 (4H, s), 7.57 (1H, m), 7.75 (3H, m), 9.30 (2H, br s)

LC (50/80) 93.5%, 4.63 min

Example 109. 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide (142)

This material was prepared from 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]azetidine hydrochloride (141) (0.234 mmol), *tert*-butyl isocyanate (0.234 mmol) and MP-carbonate (2.62 mmol/g, 0.702 mmol) using the procedure described for compound (10) (78.7 mg, 69%).

NMR (400MHz, d^6 -DMSO) δ_H 1.20 (9H, s), 3.53 (1H, m), 3.69 (1H, m), 3.85 (2H, m), 4.25 (1H, m), 5.68 (1H, s), 7.35 (2H, m), 7.42 (2H, m), 7.58 (1H, m), 7.75 (3H, m)

LC (50/80) 98.0%, 7.31 min

Example 110. 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-*N*-(*iso*-propyl)azetidine-1-carboxamide (143)

This material was prepared from 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzyloxy]azetidine hydrochloride (141) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 1.00 (6H, d, J 6.5 Hz), 3.53 (1H, m), 3.67 (2H, m), 3.86 (2H, m), 4.28 (1H, m), 5.78 (1H, s), 7.35 (2H, m), 7.42 (2H, m), 7.58 (1H, m), 7.75 (3H, m)

LC (50/80) 95.0%, 6.85 min

Example 111. 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-*N*-(*sec*-butyl)azetidine-1-carboxamide (144)

This material was prepared from 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzyloxy]azetidine hydrochloride (141) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 0.79 (3H, m), 0.97 (3H, m), 1.34 (2H, m), 3.45 (1H, m),
 5 3.55 (1H, m), 3.70 (1H, m), 3.86 (2H, m), 4.30 (1H, m), 5.79 (1H, s), 7.35 (2H, m), 7.42
 (2H, m), 7.58 (1H, m), 7.75 (3H, m)

LC (50/80) 99.0%, 7.18 min

Example 112. 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-*N*-(benzyl)azetidine-1-carboxamide (145)

This material was prepared from 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzyloxy]azetidine hydrochloride (141) and the corresponding isocyanate using the procedure described for compound (10).

NMR (400MHz, d^6 -DMSO) δ_H 3.61 (1H, m), 3.75 (1H, m), 3.92 (2H, m), 4.16 (2H, m),
 15 4.30 (1H, m), 5.80 (1H, s), 6.87 (1H, m), 7.21 (3H, m), 7.28 (2H, m), 7.35 (2H, m), 7.43
 (2H, m), 7.57 (1H, m), 7.76 (3H, m)

LC (50/80) 99.0%, 7.76 min

Example 113. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(1-adamantyl)azetidine-1-carboxamide (146)

This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) (0.55 mmol) and 1-adamantyl isocyanate (0.55 mmol) using the procedure described for compound (10) (229 mg, 83%).

MS 519 $[M + H]^+$

25 LC (50/80) 99.6%, 8.45 min

Example 114. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(cyclohexyl)azetidine-1-carboxamide (147)

This material was prepared from 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine
 30 hydrochloride (98) (0.55 mmol) and cyclohexyl isocyanate (0.55 mmol) using the procedure described for compound (10) (146 mg, 59%).

MS 467 $[M + H]^+$

LC (50/80) 99.8%, 7.32 min

Example 115. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(*tert*-amyl)azetidine-1-carboxamide (148)

Compound (98) was converted to the corresponding free-base by partitioning between
5 dichloromethane and 0.5N sodium hydroxide.

To a stirred solution of triphosgene (187 mg, 0.63 mmol) in dry dichloromethane (5 mL) at
0 °C was added portionwise over 40 min a solution of the free-base of compound (31)
(1.66 mmol) in dry dichloromethane (10 mL). After 20 min, a 5 mL aliquot of the reaction
mixture was rapidly added to triethylamine (230 µL) and *tert*-amylamine (66 µL) and the
10 resultant mixture was shaken at ambient temperature for 72 h. The reaction mixture was
washed with 0.2N hydrochloric acid and the organics were loaded onto an SCX-2 (2 g)
cartridge, then eluted with EtOAc followed by MeOH. The combined organics were
concentrated *in vacuo*, then purified by flash column chromatography [SiO₂; ethyl
acetate:*iso*-hexane (30:70 → 50:50)] to afford the desired product as an orange oil (30 mg,
15 12%)

MS 455 [M + H]⁺

LC (50/80) 92.3%, 7.22 min

Preparation of 2-(trifluoromethyl)-4'-methylbenzhydrol (149)

20 This material was prepared from 2-(trifluoromethyl)phenylmagnesium bromide (16 mmol)
and *p*-tolualdehyde (1.82 mL, 15 mmol) using the procedure described for compound (96)
(4.28 g, 100%).

LC (50/80) 97.1%, 4.76 min

25

Preparation of 1-benzhydryl-3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]azetidine (150)

This material was prepared from 1-benzhydryl-3-azetidinol (1) (7.5 mmol) and 2-
(trifluoromethyl)-4'-methylbenzhydrol (149) (15 mmol) using the procedure described for
30 compound (3). Flash column chromatography [SiO₂; ethyl acetate – *iso*-hexane (5:95)]
afforded a yellow gum (4.41 g) which was used in the next step without further
purification.

Preparation of 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]azetidine hydrochloride (151)

This material was prepared from 1-benzhydryl-3-[2-(trifluoromethyl)-4'-methylbenzyloxy]azetidine (150) (7.5 mmol) using the procedure described for compound
5 (9). Crystallisation from DIPE-MeOH afforded the product as a white solid (1.39 g, 54%).

Example 116. 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]-*N*-(1-adamantyl)-azetidine-1-carboxamide (152)

This material was prepared from 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]azetidine
10 hydrochloride (151) (0.56 mmol) and 1-adamantyl isocyanate (0.56 mmol) using the procedure described for compound (10). The desired product was obtained as a white foam (264 mg, 94%).

NMR

LC (50/80) 98.1%, 8.20 min

15

Example 117. 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]-*N*-(*tert*-butyl)-azetidine-1-carboxamide (153)

This material was prepared from 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]azetidine hydrochloride (151) (0.56 mmol) and *tert*-butyl isocyanate (0.56 mmol) using the
20 procedure described for compound (10). The desired product was obtained as a colourless glass which gave a white solid on scratching (232 mg, 98%).

MS 420 [M + H]⁺

LC (50/80) 98.7%, 6.54 min

Example 118. 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]-*N*-(cyclohexyl)-azetidine-1-carboxamide (154)

This material was prepared from 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]azetidine hydrochloride (151) (0.56 mmol) and cyclohexyl isocyanate (0.56 mmol) using the
30 procedure described for compound (10). The desired product was obtained as a white foam (230 mg, 91%).

MS 447 [M + H]⁺

LC (50/80) 99.9%, 7.11 min

Preparation of 2-(trifluoromethyl)-4'-methoxybenzhydrol (155)

This material was prepared from 2-(trifluoromethyl)phenylmagnesium bromide (16 mmol) and *p*-anisaldehyde (1.86 mL, 15 mmol) using the procedure described for compound (96) (4.34 g, 100%).

5 LC (50/80) 97.2%, 3.62 min

Preparation of 1-benzhydryl-3-[2-(trifluoromethyl)-4'-methoxybenzhydryloxy]azetidine (156)

10 This material was prepared from 1-benzhydryl-3-azetidinol (1) (7.5 mmol) and 2-(trifluoromethyl)-4'-methoxybenzhydrol (155) (15 mmol) using the procedure described for compound (3). Flash column chromatography [SiO₂; ethyl acetate – *iso*-hexane (10:90 → 20:80)] afforded a pale yellow gum (2.73 g) which was used in the next step without further purification.

15 Preparation of 3-[2-(trifluoromethyl)-4'-methoxybenzhydryloxy]azetidine (157)

The corresponding hydrochloride salt was prepared from 1-benzhydryl-3-[2-(trifluoromethyl)-4'-methoxybenzyloxy]azetidine (156) (7.5 mmol) using the procedure described for compound (9). Due to the presence of impurities, the salt was partitioned between aqueous base and an organic solvent, the organic phase dried (MgSO₄) and
20 evaporated to afford the desired product as a colourless oil (730 mg, 29%).

Example 119. 3-[2-(trifluoromethyl)-4'-methoxybenzhydryloxy]-*N*-(1-adamantyl)-azetidine-1-carboxamide (158)

To a solution of 3-[2-(trifluoromethyl)-4'-methoxybenzhydryloxy]azetidine (157) (100 mg, 0.30 mmol) in anhydrous DCM (4 mL) was added MP-carbonate (3.01 mmol/g; 100 mg, 0.30 mmol) and 1-adamantyl isocyanate (55 mg, 0.30 mmol). The resultant mixture was shaken at ambient temperature for 5 h, after which time it was poured onto a DCM-wetted SCX-2 (1 g) cartridge. Elution with DCM (6 mL) followed by DCM-MeOH (6 mL), then removal of solvent *in vacuo* afforded the desired product as a white foam (140 mg, 92%).

30 MS 515 [M + H]⁺

LC (50/80) 97.9%, 7.86 min

Example 120. 3-[2-(trifluoromethyl)-4'-methoxybenzhydryloxy]-*N*-(*tert*-butyl)-azetidine-1-carboxamide (159)

To a solution of 3-[2-(trifluoromethyl)-4'-methoxybenzhydryloxy]azetidine (157) (100 mg, 0.30 mmol) in anhydrous DCM (4 mL) was added MP-carbonate (3.01 mmol/g; 100 mg, 0.30 mmol) and *tert*-butyl isocyanate (35 μ L, 0.30 mmol). The resultant mixture was shaken at ambient temperature for 5 h, after which time it was poured onto a DCM-wetted SCX-2 (1 g) cartridge. The sample was eluted with DCM (6 mL) followed by DCM-MeOH (6 mL), then evaporated. Purification by flash column chromatography [SiO₂; ethyl acetate – *iso*-hexane (35:65 \rightarrow 50:50)] afforded the desired product as a colourless glass (90 mg, 70%).

MS 437 [M + H]⁺

LC (50/80) 99.5%, 6.12 min

Preparation of 2-(trifluoromethyl)-4'-fluorobenzhydrol (160)

This material was prepared from 2-(trifluoromethyl)phenylmagnesium bromide (16 mmol) and 4-fluorobenzaldehyde (1.64 mL, 15 mmol) using the procedure described for compound (96) (4.27 g, 100%).

LC (50/80) 99.3%, 4.37 min

Preparation of 1-benzhydryl-3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]azetidine (161)

This material was prepared from 1-benzhydryl-3-azetidinol (1) (7.5 mmol) and 2-(trifluoromethyl)-4'-fluorobenzhydrol (160) (15 mmol) using the procedure described for compound (3). After basic aqueous workup, the crude product was used in the next step without further purification.

Preparation of 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]azetidine hydrochloride (162)

This material was prepared from 1-benzhydryl-3-[2-(trifluoromethyl)-4'-fluorobenzyloxy]azetidine (161) (7.5 mmol) using the procedure described for compound (9). Crystallisation from DIPE-MeOH afforded the product as a white solid (1.49 g, 55%).

LC (50/80) 99.6%, 2.30 min

Example 121. 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(1-adamantyl)-azetidine-1-carboxamide (163)

To a solution of 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]azetidine hydrochloride (162) (200 mg, 0.55 mmol) in anhydrous DCM (5 mL) was added MP-carbonate (3.01 mmol/g; 550 mg, 1.65 mmol) and 1-adamantyl isocyanate (101 mg, 0.55 mmol). The resultant mixture was shaken at ambient temperature for 16 h, after which time it was poured onto a DCM-wetted SCX-2 (1 g) cartridge. The sample was eluted with DCM (16 mL), then evaporated to afford the desired product as a white foam (257 mg, 92%).

MS 503 $[M + H]^+$

LC (50/80) 99.3%, 7.89 min

Example 122. 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(*tert*-butyl)azetidine-1-carboxamide (164)

To a solution of 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]azetidine hydrochloride (162) (200 mg, 0.55 mmol) in anhydrous DCM (5 mL) was added MP-carbonate (3.01 mmol/g; 550 mg, 1.65 mmol) and *tert*-butyl isocyanate (65 μ L, 0.55 mmol). The resultant mixture was shaken at ambient temperature for 16 h, after which time it was poured onto a DCM-wetted SCX-2 (1 g) cartridge. The sample was eluted with DCM (16 mL), then evaporated to afford the desired product as a colourless glass (204 mg, 87%).

MS 425 $[M + H]^+$

LC (50/80) 98.0%, 6.14 min

Example 123. 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(cyclohexyl)-azetidine-1-carboxamide (165)

To a solution of 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]azetidine hydrochloride (162) (200 mg, 0.55 mmol) in anhydrous DCM (5 mL) was added MP-carbonate (3.01 mmol/g; 550 mg, 1.65 mmol) and cyclohexyl isocyanate (72 μ L, 0.55 mmol). The resultant mixture was shaken at ambient temperature for 16 h, after which time it was poured onto a DCM-wetted SCX-2 (1 g) cartridge. The sample was eluted with DCM (16 mL), then evaporated to afford the desired product as a colourless glass (194 mg, 78%).

MS 451 $[M + H]^+$

LC (50/80) 99.8%, 6.82 min

Example 124. 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(allyl)azetidine-1-carboxamide (166)

To a solution of 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]azetidine hydrochloride (98) (100 mg, 0.28 mmol) in anhydrous DCM (3 mL) was added MP-carbonate (3.01 mmol/g; 275 mg, 0.84 mmol) and allyl isocyanate (25 μ L, 0.28 mmol). The resultant mixture was shaken at ambient temperature for 16 h, after which time it was poured onto a DCM-wetted SCX-2 (1 g) cartridge. The sample was eluted with DCM (18 mL), then evaporated to afford the desired product (72 mg, 61%).

MS 425 $[M + H]^+$

LC (50/80) 98.1%, 6.25 min

Example 125. 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide (167)

To a solution of 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]azetidine hydrochloride (118) (100 mg, 0.26 mmol) in anhydrous DCM (5 mL) was added MP-carbonate (3.10 mmol/g; 250 mg, 0.84 mmol) and 1-adamantyl isocyanate (47 mg, 0.26 mmol). The resultant mixture was shaken at ambient temperature for 16 h, after which time it was poured onto a DCM-wetted SCX-2 (1 g) cartridge. The sample was eluted with DCM (18 mL), then evaporated to afford the desired product as a white, crystalline solid (70 mg, 51%).

MS 531 $[M + H]^+$

LC (50/80) 93.3%, 8.56 min

Example 126. 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide (168)

To a solution of 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]azetidine hydrochloride (118) (100 mg, 0.26 mmol) in anhydrous DCM (5 mL) was added MP-carbonate (3.10 mmol/g; 250 mg, 0.84 mmol) and cyclohexyl isocyanate (33 μ L, 0.26 mmol). The resultant mixture was shaken at ambient temperature for 16 h, after which time it was poured onto a DCM-wetted SCX-2 (1 g) cartridge. The sample was eluted with DCM (18 mL), then evaporated to afford the desired product as a white, crystalline solid (65 mg, 52%).

MS 479 $[M + H]^+$

LC (50/80) 96.8%, 7.46 min

Preparation of 2-(trifluoromethyl)-4'-(methylsulfonyl)benzhydrol (169)

- 5 This material was prepared from 2-(trifluoromethyl)phenylmagnesium bromide (14.5 mmol) and 4-(methylsulfonyl)benzaldehyde (2.68 g, 13.8 mmol) using the procedure described for compound (96). The product was obtained as an amber gum (4.95 g, 100%).
LC (80/20) 98.9%, 0.46 min

10 **Preparation of 1-benzhydryl-3-[2-(trifluoromethyl)-4'-(methylsulfonyl)benzhydroyloxy]azetidine (170)**

- This material was prepared from 1-benzhydryl-3-azetidinol (1) (6.9 mmol) and 2-(trifluoromethyl)-4'-(methylsulfonyl)benzhydrol (169) (13.8 mmol) using the procedure described for compound (3). After basic aqueous workup, the crude product was partially
15 purified by flash column chromatography [SiO_2 ; ethyl acetate – *iso*-hexane (30:70 → 80:20)] to afford an off-white foam (1.69 g) which was used directly in the next step without further purification.

20 **Preparation of 3-[2-(trifluoromethyl)-4'-(methylsulfonyl)benzhydroyloxy]azetidine (171)**

- This material was prepared from 1-benzhydryl-3-[2-(trifluoromethyl)-4'-(methylsulfonyl)benzhydroyloxy]azetidine (170) (6.9 mmol) using the procedure described for compound (4). After basic aqueous workup, purification by flash column chromatography [SiO_2 ; ethyl acetate – methanol (90:10) → ethyl acetate – methanol –
25 ammonium hydroxide (90:10:5)] afforded the desired product as a pale yellow oil (234 mg, 9% over 2 steps).

MS 386 $[M + H]^+$

LC (50/80) 89.8%, 6.49 min

30 **Example 127. 3-[2-(trifluoromethyl)-4'-(methylsulfonyl)benzhydroyloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide (172)**

To a solution of 3-[2-(trifluoromethyl)-4'-(methylsulfonyl)benzhydroyloxy]azetidine (171) (222 mg, 0.58 mmol) in anhydrous DCM (7 mL) was added molecular sieves and *tert*-

butyl isocyanate (68 μ L, 0.58 mmol). After shaking at ambient temperature for 16 h, the mixture was poured onto a DCM-wet SCX-2 cartridge (2 g). Elution with DCM (24 mL) and evaporation afforded the desired product as a pale yellow solid (188 mg, 67%).

MS 485 $[M + H]^+$

5 LC (50/80) 97.6%, 4.16 min

Preparation of 2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydrol (173)

This material was prepared from 2-(trifluoromethyl)phenylmagnesium bromide (16 mmol) and 4-(difluoromethoxy)benzaldehyde (2.09 mL, 15 mmol) using the procedure described
10 for compound (96). The product was obtained as an amber gum (3.05 g, 64%).

LC (80/20) 97.6%, 0.59 min

Preparation of 1-benzhydryl-3-[2-(trifluoromethyl)-4'-(difluoromethoxy)-benzhydryloxy]azetidine (174)

15 This material was prepared from 1-benzhydryl-3-azetidinol (1) (1.12 g, 4.7 mmol) and 2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydrol (173) (3.0 g, 9.4 mmol) using the procedure described for compound (3). After basic aqueous workup, the crude product was partially purified by flash column chromatography [SiO_2 ; ethyl acetate – *iso*-hexane (10:90 \rightarrow 15:85)] to afford an amber gum (2.83 g) which was used directly in the next step
20 without further purification.

Preparation of 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]azetidine hydrochloride (175)

To a stirred solution of 1-benzhydryl-3-[2-(trifluoromethyl)-4'-(difluoro-
25 methoxy)benzhydryloxy]azetidine (174) (2.73 g from previous step – assumed 4.7 mmol) in DCM (40 mL), cooled in ice-water bath, was added 1-chloroethyl chloroformate (1 mL, 9.4 mmol). After 1 h, the mixture was allowed to warm to ambient temperature. After a further 5.5 h, the mixture was concentrated under reduced pressure, methanol (40 mL) was added, and the mixture was stirred for 16 h. The mixture was concentrated under reduced
30 pressure, then dissolved in *iso*-hexane (4 mL) – DIPE (30 mL) – MeOH (2 mL). Upon stirring, a precipitate formed. The mixture was cooled in ice-water bath for 15 min. Filtration and washing with ice-cold DIPE-*iso*-hexane (1:1) afforded the desired product as a white solid (920 mg, 48% over 2 steps).

MS 374 [M + H]⁺

LC (50/80) 98.5%, 3.54 min

Example 128. 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide (176)

To a solution of 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]azetidine hydrochloride (175) (100 mg, 0.24 mmol) in anhydrous DCM (4 mL) was added MP-carbonate (2.62 mmol/g; 280 mg, 0.72 mmol), molecular sieves and *tert*-butyl isocyanate (29 µL, 0.24 mmol). After shaking at ambient temperature for 2 h, the mixture was poured onto a DCM-wet SCX-2 cartridge (2 g). Elution with DCM (20 mL) and evaporation afforded the desired product (90 mg, 78%).

MS 473 [M + H]⁺

LC (50/80) 96.5%, 6.34 min

Example 129. 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-*N*-(*sec*-butyl)azetidine-1-carboxamide (177)

To a solution of 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]azetidine hydrochloride (175) (100 mg, 0.24 mmol) in anhydrous DCM (4 mL) was added MP-carbonate (2.62 mmol/g; 280 mg, 0.72 mmol), molecular sieves and *sec*-butyl isocyanate (29 µL, 0.24 mmol). After shaking at ambient temperature for 2 h, the mixture was poured onto a DCM-wet SCX-2 cartridge (2 g). Elution with DCM (20 mL) and evaporation afforded the desired product (81 mg, 70%).

MS 473 [M + H]⁺

LC (50/80) 99.8%, 6.17 min

25

Example 130. 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-*N*-(*iso*-propyl)azetidine-1-carboxamide (178)

To a solution of 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]azetidine hydrochloride (175) (100 mg, 0.24 mmol) in anhydrous DCM (4 mL) was added MP-carbonate (2.62 mmol/g; 280 mg, 0.72 mmol), molecular sieves and *iso*-propyl isocyanate (25 µL, 0.24 mmol). After shaking at ambient temperature for 2 h, the mixture was poured

30

onto a DCM-wet SCX-2 cartridge (2 g). Elution with DCM (20 mL) and evaporation afforded the desired product (74 mg, 66%).

MS 459 $[M + H]^+$

LC (50/80) 99.8%, 5.79 min

5

Example 131. 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide (179)

To a solution of 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]azetidine hydrochloride (175) (100 mg, 0.24 mmol) in anhydrous DCM (4 mL) was added MP-carbonate (2.62 mmol/g; 280 mg, 0.72 mmol), molecular sieves and cyclohexyl isocyanate (32 μ L, 0.24 mmol). After shaking at ambient temperature for 2 h, the mixture was poured onto a DCM-wet SCX-2 cartridge (2 g). Elution with DCM (20 mL) and evaporation afforded the desired product (91 mg, 75%).

MS 499 $[M + H]^+$

15 LC (50/80) 97.0%, 5.63 min

Example 132. 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(allyl)azetidine-1-carboxamide (180)

To a solution of 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]azetidine hydrochloride (175) (100 mg, 0.24 mmol) in anhydrous DCM (4 mL) was added MP-carbonate (2.62 mmol/g; 280 mg, 0.72 mmol), molecular sieves and allyl isocyanate (22 μ L, 0.24 mmol). After shaking at ambient temperature for 2 h, the mixture was poured onto a DCM-wet SCX-2 cartridge (2 g). Elution with DCM (20 mL) and evaporation afforded the desired product (68 mg, 61%).

25 MS 457 $[M + H]^+$

LC (50/80) 100.0%, 6.90 min

Example 133. 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(*sec*-butyl)azetidine-1-carboxamide (181)

30 To a solution of 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]azetidine hydrochloride (162) (150 mg, 0.42 mmol) in anhydrous DCM (4 mL) was added MP-carbonate (2.62 mmol/g; 475 mg, 1.26 mmol), molecular sieves and *sec*-butyl isocyanate (49 μ L, 0.42 mmol). The resultant mixture was shaken at ambient temperature for 16 h, after which

time it was poured onto a DCM-wetted SCX-2 (1 g) cartridge. The sample was eluted with DCM (24 mL), then evaporated to afford the desired product as a colourless gum (135 mg, 77%).

MS 425 $[M + H]^+$

5 LC (50/80) 99.0%, 6.21 min

Example 134. 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(*iso*-propyl)-azetidine-1-carboxamide (182)

To a solution of 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]azetidine hydrochloride
10 (162) (150 mg, 0.42 mmol) in anhydrous DCM (4 mL) was added MP-carbonate (2.62 mmol/g; 475 mg, 1.26 mmol), molecular sieves and *iso*-propyl isocyanate (42 μ L, 0.42 mmol). The resultant mixture was shaken at ambient temperature for 16 h, after which time it was poured onto a DCM-wetted SCX-2 (1 g) cartridge. The sample was eluted with DCM (24 mL), then evaporated to afford the desired product as a colourless glass which
15 gave a white solid on scratching (126 mg, 74%).

MS 411 $[M + H]^+$

LC (50/80) 98.9%, 5.77 min

Example 135. 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-[(*S*)- α -methylbenzyl]azetidine-1-carboxamide (183)

To a solution of 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]azetidine hydrochloride
(162) (150 mg, 0.42 mmol) in anhydrous DCM (4 mL) was added MP-carbonate (2.62 mmol/g; 475 mg, 1.26 mmol), molecular sieves and (*S*)- α -methylbenzyl isocyanate (60 μ L, 0.42 mmol). The resultant mixture was shaken at ambient temperature for 16 h, after
25 which time it was poured onto a DCM-wetted SCX-2 (1 g) cartridge. The sample was eluted with DCM (24 mL), then evaporated to afford the desired product as a colourless glass which gave a white solid on scratching (136 mg, 69%).

MS 473 $[M + H]^+$

LC (50/80) 99.0%, 6.93 min

30

Example 136. 3-[2-(trifluoromethyl)-2'-fluoro-4'-(1-piperidinylloxomethyl)-benzhydryloxy]-N-(*tert*-butyl)azetidine-1-carboxamide (184)

and

Example 137. 3-[2-(trifluoromethyl)-2'-fluorobenzhydryloxy]-N-(*tert*-butyl)azetidine-1-carboxamide (185)

A mixture of 3-[2-(trifluoromethyl)-2'-fluoro-4'-bromobenzhydryloxy]-N-(*tert*-butyl)-azetidine-1-carboxamide (115) (106 mg, 0.21 mmol), diglyme (1 mL), 4M K₂CO₃ (0.2 mL), toluene (1 mL), (*R/S*)-BINAP (12.1 mg), Herrmann's catalyst [CAS: 172418-32-5] (7.0 mg), Mo(CO)₆ (26.0 mg) and piperidine (27 µL) was irradiated, with stirring, in a microwave reactor. Power was applied and varied to maintain the reaction at a temperature of 150 C for a period of 15 min. After this time, the reaction was allowed to cool, then was filtered and evaporated. Purification by flash column chromatography [SiO₂; ethyl acetate – iso-hexane (30:70 → 70:30)] afforded 3-[2-(trifluoromethyl)-2'-fluoro-4'-(1-piperidinyloxomethyl)benzhydryloxy]-N-(*tert*-butyl)azetidine-1-carboxamide (184) as a pale yellow solid (13.2 mg, 12%)

MS 536 [M + H]⁺
LC 69.3%, 5.69 min

and 3-[2-(trifluoromethyl)-2'-fluorobenzhydryloxy]-N-(*tert*-butyl)azetidine-1-carboxamide (185) as a pale yellow gum (16.2 mg, 18%)

MS 425 [M + H]⁺
LC 61.9%, 6.08 min

Example 138. 3-[(*R*^{*})-2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(*tert*-butyl)-azetidine-1-carboxamide (186)

and

Example 139. 3-[(*S*^{*})-2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(*tert*-butyl)-azetidine-1-carboxamide (187)

The racemic compound 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(*tert*-butyl)azetidine-1-carboxamide (99) was separated into samples which were significantly enriched in each single enantiomeric form. Thus, a sample of the racemic mixture (300 mg) was dissolved in 6 mL of an IPA – hexane (10:90) mix. This mixture was repeatedly injected (11 x 500 µL) onto a Daicel Chiralpak® ADTM chiral HPLC column (250mm x 21mm ID) fitted with a guard column (50 mm x 21mm ID) [eluent: IPA – hexane (10:90); flow-rate: 10 mL/min; wavelength: 235 nm]. The combined first-eluting enantiomer (arbitrarily assigned R^{*} unknown absolute stereochemistry) fractions) were evaporated to

afford 3-[(*R**)-2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide as a white solid (103.5 mg, 37.6%).

MS 441 [M + H]⁺

LC (50/80) 98.8%, 7.08 min

5 LC [Chiral AD; IPA – hexane (10:90)] 97.3%, 7.90 min; 100% *ee*

Mixed fractions were evaporated to afford a white solid (59.8 mg, 21.7%).

The combined second-eluting enantiomer (arbitrarily assigned *S** unknown absolute stereochemistry) fractions) were evaporated to afford 3-[(*S**)-2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide as a white solid (70.0 mg, 25.5%).

MS 441 [M + H]⁺

LC (50/80) 98.7%, 7.06 min

15 LC [Chiral AD; IPA – hexane (5:95)] 88.5%, 16.46 min; 9.2%, 14.27 min; 81% *ee*

Example 140. 3-[(*R**)-2-(trifluoromethyl)-4'-(methylsulphonyl)benzhydryloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide (188)

and

20 **Example 141.** 3-[(*S**)-2-(trifluoromethyl)-4'-(methylsulphonyl)benzhydryloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide (189)

The racemic compound 3-[2-(trifluoromethyl)-4'-(methylsulfonyl)benzhydryloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide (172) was separated into samples which were significantly enriched in each single enantiomeric form. Thus, a sample of the racemic mixture (87 mg) was dissolved in 800 μL of an IPA – hexane (25:75) mix. This mixture was repeatedly injected (5 x 50 μL) onto a Daicel Chiralpak® ADTM chiral HPLC column (250mm x 21mm ID) fitted with a guard column (50 mm x 21mm ID) [eluent: IPA – hexane (25:75); flow-rate: 15 mL/min; wavelength: 235 nm]. The combined first-eluting enantiomer (arbitrarily assigned *R** unknown absolute stereochemistry) fractions) were evaporated to afford 3-[(*R**)-2-(trifluoromethyl)-4'-(methylsulfonyl)benzhydryloxy]-*N*-(*tert*-butyl)-azetidine-1-carboxamide as a white solid.

MS 485 [M + H]⁺

LC (50/80) 99.9%, 3.97 min

LC [Chiral AD; IPA – hexane (30:70)] 97.1%, 7.59 min; 100% *ee*

The combined second-eluting enantiomer (arbitrarily assigned *S** unknown absolute stereochemistry) fractions) were evaporated to afford 3-[(*S**)-2-(trifluoromethyl)-4'-(methylsulfonyl)benzhydryloxy]-*N*-(*tert*-butyl)azetidine-1-carboxamide as a white solid.


5 MS 485 [M + H]⁺

LC (50/80) 99.6%, 4.02 min

LC [Chiral AD; IPA – hexane (30:70)] 81.8%, 11.6 min; 11.1%, 7.74 min; 76% *ee*

CLAIMS

1. A compound of formula (I):



(I)

wherein:

R^1 and R^2 are independently selected from aryl; and

R^3 is hydrogen or alkyl;

or a pharmaceutically acceptable salt or prodrug thereof,


- 10 wherein at least one of R^1 and R^2 has a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [-CH-O-] group.

2. A compound according to claim 1 wherein R^1 and R^2 are independently selected from mono-cyclic aromatic groups.

15

3. A compound according to claim 1 or 2 wherein R^1 and R^2 are independently selected from phenyl.

4. A compound according to claim 1, 2 or 3 wherein R^1 and R^2 are independently selected
20 from a group of formula:



wherein R^4 , R^5 and R^6 are independently selected from hydrogen, halo, alkyl, thioalkyl, alkoxy, alkylsulfonyl, amino, mono- and di-alkyl amino, mono- and di-aryl amino, alkylarylamino, $NR^{14}C(O)R^{15}$, $NR^{14}SO_2R^{16}$, $COOR^{15}$, $OC(O)R^{16}$, $CONR^7R^8$ and $SO_2NR^7R^8$,

wherein R^7 and R^8 are independently selected from hydrogen and alkyl or may form a 5 or 6 membered ring optionally containing 1 or 2 additional heteroatoms selected from N, O and S; and wherein R^{14} is selected from H and lower alkyl, R^{15} is selected from H, alkyl, aryl and heteroaryl and R^{16} is selected from alkyl, aryl and heteroaryl.

5

5. A compound according to claim 1, 2, 3 or 4 wherein R^1 and R^2 are different.

6. A compound according to claim 4 or 5 wherein R^4 , R^5 and R^6 are independently selected from fluoro, chloro, bromo and iodo.

10

7. A compound according to claim 4 or 5 wherein R^4 , R^5 and R^6 are independently selected from alkyl, thioalkyl, alkoxy and alkylsulfonyl wherein the alkyl group is selected from lower alkyl.

15

8. A compound according to claim 4 or 5 wherein R^4 , R^5 and R^6 are independently selected from trifluoromethyl and difluoromethoxy.

9. A compound according to claim 4 or 5 wherein one or two of R^4 , R^5 and R^6 are hydrogen.

20

10. A compound according to claim 4 or 5 wherein R^{14} is selected from H.

11. A compound according to claim 4 or 5 wherein R^{15} and R^{16} are independently selected from alkyl.

25


12. A compound according to claim 4 or 5 wherein R^{15} and R^{16} are independently selected from lower alkyl.

13. A compound according to any preceding claim wherein R^3 is selected from alkyl.

30

14. A compound according to any preceding claim wherein R^3 is selected from tertiary butyl, isobutyl, sec-butyl and isopropyl.

15. A compound according to any preceding claim wherein R^3 is selected from :



wherein n is 0 or 1;

5 m is 0, 1, 2 or 3;

R^9 , R^{10} , R^{11} and R^{12} are selected from hydrogen, alkyl, hydroxy, alkoxy, thioalkyl, amino, mono- and di-alkyl amino, alkoxycarbonyl and R^{13} ;

wherein R^{13} is selected from aryl, heteroaryl and non-aromatic heterocyclic optionally substituted by one or more groups selected from alkyl, halogen, alkoxy, oxo, aryl, heteroaryl
10 and non-aromatic heterocycle.

16. A compound according to claim 15 wherein m is 0 or 1.

17. A compound according to claim 15 wherein n is 0.

15

18. A compound according to claim 13 wherein R^3 is selected from cyclopentyl, cyclohexyl, norbornanyl and adamantyl.

19. A compound according to claim 1 wherein the compound is selected from:

3-(2,4,4'-trichlorobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2-thiophen-2-yl ethyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(cyclopropylmethyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2,3-dihydrobenzofuran-5-yl-methyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2,5-dimethylfuran-3-yl-methyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2,3-Dihydro-benzo[1,4]dioxin-2-yl-methyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(5-methyl-isoxazol-3-yl-methyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-[(R)-sec-butyl]azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2-bromothiophen-3-yl-methyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-[(S)-sec-butyl]azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(thiophen-3-yl-methyl)azetidine-1-carboxamide

3-(2,4'-dichlorobenzhydryloxy)-N-(2-methoxyphenylmethyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(2-furanylmethyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(3-ethoxypropyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(2-tetrahydrofuranylmethyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(exo-2-norbornanyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(1-phenylpropyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-[(R)-a-methylbenzyl]azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-[(R)-1-(3-methoxyphenyl)ethyl]azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-[(S)-1-(3-methoxyphenyl)ethyl]azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(n-butyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(ethyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-[(S)-a-methyl-benzyl]azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(2,2,4-trimethylpent-4-yl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(cyclopentyl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(2,2,4-trimethylpent-4-yl)azetidine-1-carboxamide
 3-(2,4'-dichlorobenzhydryloxy)-N-(2-methylbut-2-yl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-2'-fluoro-4'-bromobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(benzyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide

- 3-[2-(trifluoromethyl)-4-fluoro-4'-chlorobenzhydryloxy]-N-(benzyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)benzhydryloxy]-N-(benzyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(trifluoromethoxy)benzhydryloxy]-N-(benzyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(tert-amyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methylbenzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methoxybenzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-methoxybenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(allyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(1-adamantyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(methylthio)benzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide
- 3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide

3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(iso-propyl)azetidine-1-carboxamide

3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(cyclohexyl)azetidine-1-carboxamide

3-[2-(trifluoromethyl)-4'-(difluoromethoxy)benzhydryloxy]-N-(allyl)azetidine-1-carboxamide

3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-(sec-butyl)azetidine-1-carboxamide

3-[2-(trifluoromethyl)-4'-fluorobenzhydryloxy]-N-[(S)-a-methylbenzyl]azetidine-1-carboxamide

3-[2-(trifluoromethyl)-2'-fluoro-4'-(1-piperidinyloxomethyl)benzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide

3-[2-(trifluoromethyl)-2'-fluorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide, and

3-[(S*)-2-(trifluoromethyl)-4'-chlorobenzhydryloxy]-N-(tert-butyl)azetidine-1-carboxamide.

20. For use in therapy, a compound according to any one of claims 1 to 19.

21. Use of a compound according to any of claims 1 to 19 in the manufacture of a medicament for the treatment of a disorder mediated by CB₁ receptors.

22. A method of treatment of a disorder mediated by CB₁ receptors comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) as defined in any of claims 1 to 19, or a pharmaceutically acceptable salt or prodrug thereof.

23. A use or method according to claim 22 wherein the compound of formula (I) is in oral medicament.

24. A use or method according to claim 21 or 22 wherein the disorder is selected from psychosis, memory deficit, cognitive disorders, attention deficit disorder, migraine, neuropathy, neuro-inflammatory disorders, cerebral vascular injuries, head trauma, anxiety disorders, depression, stress, epilepsy, dementia, distonia, Alzheimer's disease, Huntingdon's disease, Tourette's syndrome, ischaemia, pain, Parkinson's disease, schizophrenia, substance abuse disorders, smoking cessation, treatment of nicotine dependance and/or treatment of symptoms of nicotine withdrawal, gastrointestinal

disorders, eating disorders associated with excessive food intake, and non-insulin dependant diabetes mellitus.

25. A use or method according to claim 24 wherein said substance abuse disorder is
5 abuse of nicotine, alcohol and/or opiates.

26. A use or method according to claim 24 wherein said eating disorder is obesity.

27. A use or method according to claim 24 wherein said disorder is Parkinson's
10 Disease.

28. A use or method according to claim 24 for smoking cessation.

29. A use or method according to claim 24 for gastrointestinal disorders.
15

30. A use or method according to claim 24 wherein said disorder is selected from
psychosis, schizophrenia, cognitive disorders, attention deficit disorder, smoking cessation,
gastrointestinal disorders, eating disorders associated with excessive food intake, and non-
insulin dependant diabetes mellitus.
20

PCT/GB2004/001831



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.